<PAGE>
<PAGE>
SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, D.C. 20549
FORM 10-K
ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d)
OF THE SECURITIES EXCHANGE ACT OF 1934
<TABLE>
<S> <C>
FOR THE FISCAL YEAR ENDED DECEMBER 31, 1997 COMMISSION FILE NUMBER 1-6351
</TABLE>
ELI LILLY AND COMPANY
AN INDIANA CORPORATION I.R.S. EMPLOYER NUMBER 35-0470950
ADDRESS: LILLY CORPORATE CENTER, INDIANAPOLIS, INDIANA 46285
TELEPHONE NUMBER, INCLUDING AREA CODE: (317) 276-2000
SECURITIES REGISTERED PURSUANT TO SECTION 12(b) OF THE ACT:
NAME OF EACH EXCHANGE
TITLE OF EACH CLASS ON WHICH REGISTERED
------------------- -------------------
Common Stock New York and Pacific Stock Exchanges
Preferred Stock Purchase Rights New York and Pacific Stock Exchanges
8-1/8% Notes Due December 1, 2001 New York Stock Exchange
8-3/8% Notes Due December 1, 2006 New York Stock Exchange
6.57% Notes Due January 1, 2016 New York Stock Exchange
6.77% Notes Due January 1, 2036 New York Stock Exchange
SECURITIES REGISTERED PURSUANT TO SECTION 12(g) OF THE ACT: None
Indicate by check mark whether the Registrant (1) has filed all reports required
to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during
the preceding 12 months, and (2) has been subject to such filing requirements
for the past 90 days. Yes X No
--- ----
Indicate by check mark if disclosure of delinquent filers pursuant to Item 405
of Regulation S-K is not contained herein, and will not be contained, to the
best of Registrant's knowledge, in the definitive proxy statement incorporated
by reference in Part III of this Form 10-K or any amendment to this Form
10-K. [ ]
Aggregate market value of voting stock of the Registrant held by non-affiliates
as of February 13, 1998 (Common Stock): $59,637,592,293.
Number of shares of common stock outstanding as of February 13, 1998:
1,111,258,506.
Portions of the following documents have been incorporated by reference into
this report:
DOCUMENT PARTS INTO WHICH INCORPORATED
-------- -----------------------------
Registrant's Annual Report to Shareholders Parts I, II, and IV
for fiscal year ended December 31, 1997
Registrant's Proxy Statement dated March 4, 1998 Part III
<PAGE>
<PAGE>
PART I
ITEM 1. BUSINESS
Eli Lilly and Company was incorporated in 1901 under the laws of Indiana to
succeed to the drug manufacturing business founded in Indianapolis, Indiana, in
1876 by Colonel Eli Lilly. The Company*, including its subsidiaries, discovers,
develops, manufactures, and sells products and provides services in one industry
segment--Life Sciences. Products are manufactured or distributed through owned
or leased facilities in the United States, Puerto Rico, and 27 other countries.
Its products are sold in approximately 160 countries. Through its PCS Health
Systems ("PCS") and Integrated Medical Systems ("IMS") subsidiaries, the Company
provides health care management services in the United States.
Most of the Company's products were discovered or developed through the
Company's research and development activities, and the success of the Company's
business depends to a great extent on the continued introduction of new products
resulting from these research and development activities. Research efforts are
primarily directed toward discovering and developing products to diagnose and
treat diseases in human beings and animals and to increase the efficiency of
animal food production.
FINANCIAL INFORMATION RELATING TO INDUSTRY
SEGMENTS AND CLASSES OF PRODUCTS
Financial information relating to industry segments and classes of
products, set forth in the Company's 1997 Annual Report at pages 32-33 under
"Segment Information" (pages 14-15 of Exhibit 13 to this Form 10-K), is
incorporated herein by reference.
Due to several factors, including the introduction of new products by the
Company and other manufacturers, the relative contribution of any particular
Company product to consolidated net sales is not necessarily constant from year
to year, and its contribution to net income is not necessarily the same as its
contribution to consolidated net sales.
PRODUCTS AND SERVICES
PHARMACEUTICAL PRODUCTS
Pharmaceutical products include
Central-nervous-system agents, the Company's largest-selling product
group, including Prozac'r', a selective serotonin reuptake inhibitor,
indicated for the treatment of depression and, in many countries, for
bulimia and obsessive-compulsive disorder; Zyprexa'r', a product for the
treatment of schizophrenia; the Darvon'r' line of analgesic products;
and Permax'r', a treatment for Parkinsonis disease;
- --------
*The terms "Company" and "Registrant" are used interchangeably herein to refer
to Eli Lilly and Company or to Eli Lilly and Company and its consolidated
subsidiaries, as the context requires.
-1-
<PAGE>
<PAGE>
Endocrine products, including Humulin'r', human insulin produced
through recombinant DNA technology; Humalog'r', a rapid-acting
injectable human insulin analog of recombinant DNA origin; Iletin'r',
animal-source insulin in its various pharmaceutical forms; Humatrope'r',
human growth hormone produced by recombinant DNA technology; and
Evista'r', cleared for marketing in the United States in late 1997 and
launched in early 1998 for the prevention of osteoporosis in
post-menopausal women;
Anti-infectives, including the oral cephalosporin antibiotics
Ceclor'r' (cefaclor), Keflex'r', and Keftab'r', used in the treatment of
a wide range of bacterial infections; the oral carbacephem antibiotic
Lorabid'r', used to treat a variety of bacterial infections; the oral
macrolide antibiotic Dynabac'r'; the injectable cephalosporin
antibiotics Tazidime'r', Kefurox'r', and Kefzol'r', used to treat a wide
range of bacterial infections in the hospital setting; Nebcin'r', an
injectable aminoglycoside antibiotic used in hospitals to treat various
infections caused by staphylococci and Gram-negative bacteria; and
Vancocin'r' HCI, an injectable antibiotic used primarily to treat
staphylococcal infections;
An antiulcer agent, Axid'r', an H2 antagonist, indicated for the
treatment of active duodenal ulcer, for maintenance therapy for duodenal
ulcer patients after healing of an active duodenal ulcer, for reflux
esophagitis, and for benign gastric ulcer;
Cardiovascular agents, including ReoPro'r', a monoclonal antibody
product developed and manufactured by Centocor, Inc. and marketed by the
Company for use in all patients undergoing angioplasty and patients with
unstable angina who are not responding to conventional therapy and who
are scheduled to have angioplasty within 24 hours; Dobutrex'r', an
inotropic agent; and Cynt'tm', marketed outside the United States for
treatment of hypertension; and
Oncolytic agents, including Gemzar'r', indicated for treatment of
advanced or metastatic pancreatic cancer, and, in many countries outside
the United States, for treatment of non-small-cell lung cancer;
Oncovin'r', indicated for treatment of acute leukemia and, in
combination with other oncolytic agents, for treatment of several
different types of advanced cancers; Velban'r', used in a variety of
malignant neoplastic conditions; and Eldisine'r', indicated for
treatment of acute childhood leukemia resistant to other drugs.
ANIMAL HEALTH PRODUCTS
Animal health products include Tylan'r', an antibiotic used to control
certain diseases in cattle, swine, and poultry and to improve feed efficiency
and growth; Rumensin'r', a cattle feed additive that improves feed efficiency
and growth; Coban'r', Monteban'r' and Maxiban'r', anticoccidial agents for use
in poultry; Apralan'r', an antibiotic used to control enteric infections in
calves and swine; Micotil'r' and Pulmotil'r', antibiotics used to treat
respiratory disease in cattle and swine, respectively; and other products for
livestock and poultry.
HEALTH CARE MANAGEMENT SERVICES
PCS provides computer-based prescription drug claims processing, pharmacy
benefit administration and management services, mail order pharmacy services,
data management and disease-management services to health plan sponsors,
including insurance companies, third-party administrators, self-insured
employers, health maintenance organizations, and Blue
-2-
<PAGE>
<PAGE>
Cross/Blue Shield organizations that underwrite or administer prescription
benefit plans. PCS helps these customers manage prescription benefit costs by
providing drug utilization reviews, clinically-based formularies, generic
substitution programs, and disease-management programs. RECAP'r', PCS's on-line
prescription claims management system, is linked with over 95% of retail
pharmacies in the U.S. In 1996, PCS introduced a mail order pharmacy program for
its customers known as Performance Mail. Integrated Medical Systems operates
physician-based electronic communication networks, called IMS MEDACOM'r'
networks, that deliver clinical, administrative, and financial information to
hospitals, payers/managed-care plans, laboratories, and physicians. In March
1998, the Company and Electronic Data Systems Corporation (EDS) formed Kinetra,
a joint venture to develop a comprehensive, interactive electronic health
information network for physicians and other health care professionals. IMS
operations will become part of Kinetra, which is 51 percent owned by EDS and 49
percent owned by the Company.
MARKETING
Most of the Company's major products are marketed worldwide. Health care
management services are marketed primarily in the United States.
Pharmaceuticals -- United States
In the United States, the Company distributes pharmaceutical products
principally through approximately 195 independent wholesale distributing
outlets. Marketing policy is designed to assure that products are immediately
available to physicians, pharmacies, hospitals, and appropriate health care
professionals throughout the country. Five wholesale distributors in the United
States accounted for approximately 15%, 12%, 11%, 11%, and 6%, respectively, of
the Company's consolidated net sales in 1997. No other distributor accounted for
as much as 2% of consolidated net sales. The Company also sells pharmaceutical
products directly to the United States government and other manufacturers, but
those direct sales are not material to consolidated net sales.
The Company's major pharmaceutical products are promoted in the United
States under the Lilly and Dista trade names by Company sales forces employing
salaried sales representatives. These sales representatives, many of whom are
registered pharmacists, call upon physicians, wholesalers, hospitals,
managed-care organizations, retail pharmacists, and other health care
professionals. Their efforts are supported by the Company through advertising in
medical and drug journals, distribution of literature and samples of certain
products to physicians, and exhibits for use at medical meetings. In 1997, the
Company began advertising certain of its products directly to consumers in the
United States. The Company has created specialized sales forces dedicated to
specific products and product lines, such as diabetes care, Gemzar, ReoPro, and
Zyprexa. The Company has entered into licensing arrangements under which certain
products manufactured by the Company, such as Ceclor CD, Dynabac, Keftab, and
Permax, are marketed by other pharmaceutical companies.
Large purchasers of pharmaceuticals, such as managed-care groups and
government and long-term care institutions, now account for a significant
portion of total pharmaceutical purchases in the United States. The Company has
created special sales groups to service managed-care organizations, government
and long-term care institutions, hospital contract administrators, and certain
retail pharmacies. In response to competitive pressures, the Company has entered
into arrangements with a number of these organizations providing for
-3-
<PAGE>
<PAGE>
discounts or rebates on one or more Company products or other cost-sharing
arrangements. The Company has also entered into agreements with generic
pharmaceutical companies for the promotion, distribution and/or supply of
generic forms of certain of the Company's products.
Pharmaceuticals -- Outside the United States
Outside the United States, pharmaceutical products are promoted primarily
by salaried sales representatives. While the products marketed vary from country
to country, anti-infectives constitute the largest single group in total sales.
Distribution patterns vary from country to country. In recent years, the Company
has significantly expanded its marketing efforts in a number of overseas
markets, including emerging markets in Central and Eastern Europe, Latin
America, Asia and Africa.
Animal Health Products
Elanco Animal Health, a division of the Company, employs field salespeople
throughout the United States to market animal health products. Sales are made to
wholesale distributors, retailers, feed manufacturers, or producers in
conformance with varying distribution patterns applicable to the various types
of products. The Company also has an extensive sales force outside the United
States to market its animal health products.
RAW MATERIALS
Most of the principal materials used by the Company in manufacturing
operations are chemical, plant, and animal products that are available from more
than one source. Certain raw materials are available or are purchased
principally from only one source. Unavailability of certain materials from
present sources could cause an interruption in production pending establishment
of new sources or, in some cases, implementation of alternative processes.
Although the major portion of the Company's sales abroad are of products
manufactured wholly or in part abroad, a principal source of active ingredients
for these manufactured products continues to be the Company's facilities in the
United States.
PATENTS AND LICENSES
Patent protection is important to the Company's ability to successfully
commercialize its life sciences innovations. The Company owns, has applications
pending for, or is licensed under, a substantial number of patents, both in the
United States and in other countries, relating to products, product uses, and
manufacturing processes. There can be no assurance that patents will result from
the Company's pending applications. Moreover, patents relating to particular
products, uses, or processes do not preclude other manufacturers from employing
alternative processes or from successfully marketing substitute products to
compete with the patented products or uses. Outside the United States, patent
protection varies widely. In many countries, patent protection is weak or
nonexistent.
Patent protection of certain products, processes, and uses--particularly
that relating to Prozac, Axid, Gemzar, Lorabid, Zyprexa, and Evista--is
considered to be important to the operations of the Company. The United States
compound patent covering Prozac expires in 2001 and a patent for the process by
which Prozac works expires in 2003. See "Legal Proceedings" at pages 10-11 for a
discussion of certain litigation involving these two patents. In other
countries, Prozac patents generally either have expired or will expire over the
next
-4-
<PAGE>
<PAGE>
several years. Other U.S. compound patent expirations include the following:
Axid, 2002; Lorabid, 2006; and Zyprexa, 2011. The Gemzar compound patent in the
U.S. expires in 2006, but a use patent covering treatment of neoplasms with
Gemzar is in force until 2012. The Company holds a number of U.S. patents
covering Evista that the Company believes will provide exclusivity in the United
States until at least 2012.
The Company also grants licenses under patents and know-how developed by
the Company and manufactures and sells products and uses technology and know-how
under licenses from others. Royalties paid by the Company in relation to
pharmaceuticals amounted to approximately $140 million in 1997 and royalties
received were not material.
COMPETITION
The Company's pharmaceutical products compete with products manufactured by
many other companies in highly competitive markets in the United States and
throughout the world. The Company's animal health products compete on a
worldwide basis with products of pharmaceutical, chemical, and other companies
that operate animal health divisions or subsidiaries. PCS faces strong
competition from other pharmacy benefit management companies and claims
processors in the United States. For certain accounts, PCS competes with some
retail pharmacy chains, mail order programs and organized groups of independent
pharmacists.
Important competitive factors include price and demonstrated
cost-effectiveness, product characteristics and dependability, service, and
research and development of new products and processes. The introduction by
competitors of new products and processes with therapeutic or cost advantages
can result in progressive price reductions or decreased volume of sales of the
Company's products, or both. New products introduced with patent protection
usually must compete with other products already on the market at the time of
introduction or products developed by competitors after introduction.
Manufacturers of generic products typically invest far less in research and
development than research-based pharmaceutical companies and accordingly are
able to price their products significantly lower than branded products.
Therefore, upon patent expiration, branded products often face intense price
competition from generic forms of the product. In many countries outside the
United States, patent protection is weak or nonexistent. The growth of managed
care organizations has intensified price competition significantly in the United
States and in varying degrees in some other countries.
The Company believes its long-term competitive position depends upon the
success of its research and development endeavors in discovering and developing
innovative, demonstrably cost-effective products, together with increased
productivity resulting from improved manufacturing methods, marketing efforts,
and the provision of value-added services to its customers. There can be no
assurance that the Company's research and development efforts will result in
commercially successful products or that products manufactured or processes used
by the Company will not become outmoded from time to time as a result of
products or processes developed by its competitors.
GOVERNMENTAL REGULATION
For many years the Company's operations have been regulated extensively by
the federal government, to some extent by state governments, and in varying
degrees by foreign governments. The Federal Food, Drug, and Cosmetic Act, other
federal statutes and regulations, various state statutes and regulations, and
laws and regulations of foreign
-5-
<PAGE>
<PAGE>
governments govern testing, approval, production, labeling, distribution,
post-market surveillance, advertising, and promotion of most of the Company's
products. The lengthy process of laboratory testing, clinical testing, data
analysis and regulatory review necessary for required governmental approvals is
extremely costly and can significantly delay product introductions in a given
market. In addition, the Company's operations are subject to complex federal,
state, local, and foreign environmental and occupational safety laws and
regulations. PCS and its customers operate in a rapidly-changing regulatory
environment affecting all aspects of the health insurance and managed care
marketplace. It is anticipated that compliance with regulations affecting the
manufacture and sale of current products and services and the introduction of
new products and services will continue to require substantial scientific and
technical effort, time, and expense and significant capital investment.
In the United States, the Omnibus Budget Reconciliation Act of 1990
requires the Company to provide rebates to state governments on their purchases
of certain Company products under state Medicaid programs. Other cost
containment measures have been adopted or proposed by federal, state, and local
government entities that provide or pay for health care. In most international
markets, the Company operates in an environment of government-mandated cost
containment programs, which may include price controls, discounts and rebates,
restrictions on physician prescription levels, compulsory licenses and generic
substitution. The Company expects that governments inside and outside the United
States will continue to adopt a variety of measures to contain health care
costs, including pharmaceutical costs. Recently, the U.S. FDA issued for comment
a draft guidance in which FDA has asserted that it has the authority to regulate
certain communications of pharmacy benefit managers (PBMs) owned by
pharmaceutical manufacturers (such as PCS) as if those communications were made
by the manufacturer. The draft guidance also extends to certain PBMs that are
not owned by manufacturers but have contracts with them. The Company cannot
predict the extent to which its business may be affected by these or other
potential future legislative or regulatory developments.
RESEARCH AND DEVELOPMENT
The Company's research and development activities are responsible for the
discovery or development of most of the products the Company offers today. Its
commitment to research and development dates back more than 100 years. The
Company invests heavily in research and development, which management believes
is critical to long-term competitiveness in the pharmaceutical industry. The
growth in research and development expenditures and personnel over the past
several years demonstrates both the continued vitality of the Company's
commitment and the increasing costs and complexity of bringing new products to
the market. At the end of 1997, approximately 5,750 people, including a
substantial number who are physicians or scientists holding graduate or
postgraduate degrees or highly skilled technical personnel, were engaged in
pharmaceutical and animal health research and development activities. The
Company expended $1.04 billion on these research and development activities in
1995, $1.19 billion in 1996, and $1.38 billion in 1997.
The Company's research is concerned primarily with the effects of synthetic
chemicals and natural products on biological systems. The results of that
research are applied to develop products to treat diseases in humans and
animals. The primary effort is devoted to human pharmaceutical products. The
Company concentrates its pharmaceutical research and development efforts in five
therapeutic categories: central nervous system and related diseases; endocrine
diseases, including diabetes and osteoporosis; infectious diseases; cancer; and
cardiovascular diseases. The Company is engaged in biotechnology research
programs
-6-
<PAGE>
<PAGE>
involving recombinant DNA, proteins, and genomics (the development of
therapeutics through identification of disease-causing genes and their cellular
function).
In addition to the research carried on in the Company's own laboratories,
the Company sponsors and underwrites the cost of research and development by
independent organizations, including educational institutions and research-based
human health care companies, and contracts with others for the performance of
research in their facilities. It utilizes the services of physicians, hospitals,
medical schools, and other research organizations in the United States and many
other countries to establish through clinical evidence the safety and
effectiveness of new products. The Company actively seeks out opportunities to
invest in external research and technologies that hold the promise to complement
and strengthen the Company's own research efforts. These investments can take
many forms, including licensing arrangements, co-development and co-marketing
agreements, and outright acquisitions.
Extensive work is also conducted in the animal sciences, including animal
nutrition and physiology and veterinary medicine. Certain of the Company's
research and development activities relating to pharmaceutical products may be
applicable to animal health products. An example is the search for agents that
will cure infectious disease.
QUALITY ASSURANCE
The Company's success depends in great measure upon customer confidence in
the quality of the Company's products and in the integrity of the data that
support their safety and effectiveness. The quality of the Company's products
arises from the total commitment to quality in all parts of the Company,
including research and development, purchasing, facilities planning,
manufacturing, and distribution. Quality-assurance procedures have been
developed relating to the quality and integrity of the Company's scientific
information and production processes.
Control of production processes involves rigid specifications for
ingredients, equipment, facilities, manufacturing methods, packaging materials,
and labeling. Control tests are made at various stages of production processes
and on the final product to assure that the product meets all regulatory
requirements and the Company's standards. These tests may involve chemical and
physical chemical analyses, microbiological testing, testing in animals, or a
combination of these tests. Additional assurance of quality is provided by a
corporate quality-assurance group that monitors existing pharmaceutical and
animal health manufacturing procedures and systems in the parent company,
subsidiaries, and affiliates.
EXECUTIVE OFFICERS OF THE COMPANY
The following table sets forth certain information regarding the executive
officers of the Company. All but three of the executive officers have been
employed by the Company in executive or managerial positions during the last
five years. Randall L. Tobias became Chairman of the Board and Chief Executive
Officer in June 1993. He had served as Vice Chairman of the Board of AT&T from
1986 until he assumed his present position. He has been a member of the Board of
Directors of the Company since 1986. Charles E. Golden joined the Company as
Executive Vice President and Chief Financial Officer and was elected to the
Board of Directors in March 1996. He previously had held a number of executive
positions with General Motors Corporation ("GM") including Vice President of GM
and Chairman and
-7-
<PAGE>
<PAGE>
Managing Director of Vauxhall Motors Limited, a GM subsidiary in the United
Kingdom, from 1993 to 1996, Vice President and Treasurer from 1992 to 1993, and
Treasurer from 1989 to 1992. Thomas Trainer joined the Company in January 1995.
Since 1991 he had served as Vice President and Chief Information Officer of
Reebok International Ltd. Prior to joining Reebok, he was Senior Vice President
of Operations of A.C. Nielson Co.
Except as indicated in the following table, the term of office for each
executive officer expires on the date of the annual meeting of the Board of
Directors, to be held on April 20, 1998, or on the date his or her successor is
chosen and qualified. No director or executive officer of the Company has a
"family relationship" with any other director or executive officer of the
Company, as that term is defined for purposes of this disclosure requirement.
There is no understanding between any executive officer of the Company and any
other person pursuant to which the executive officer was selected.
<TABLE>
<CAPTION>
NAME AGE OFFICES
- ----------------------------------------------------------------------------------------------
<S> <C> <C>
Randall L. Tobias 56 Chairman of the Board and Chief Executive Officer
(since June 1993) and a Director
Sidney Taurel 49 President and Chief Operating Officer (since February
1996) and a Director
Charles E. Golden 51 Executive Vice President and Chief Financial Officer
(since March 1996) and a Director
August M. Watanabe, M.D. 56 Executive Vice President, Science and Technology
(since February 1996) and a Director
Mitchell E. Daniels, Jr. 48 Vice President, Corporate Strategy and Policy (since
January 1997)
Rebecca O. Goss 50 Vice President and General Counsel (since March 1995)
Pedro P. Granadillo 50 Vice President, Human Resources (since April 1993)
Bryce D. Carmine 46 President and General Manager, Eli Lilly Japan K.K.
(since May 1995)*
Alan S. Clark 63 President, U.S. Operations (since January 1997)*
Michael L. Eagle 50 Vice President, Manufacturing (since January 1994)*
Brendan P. Fox, D.V.M. 54 President, Elanco Animal Health Business Unit (since
January 1991)*
Michael E. Hanson 50 President, Internal Medicine Business Unit (since
August 1994)(retired December 31, 1997)
</TABLE>
- ----------
* Serves in office until successor is appointed.
-8-
<PAGE>
<PAGE>
<TABLE>
<CAPTION>
NAME AGE OFFICES
- ----------------------------------------------------------------------------------------------
<S> <C> <C>
James A. Harper 50 President, Endocrine Business Unit (since August 1994)*
Gerhard N. Mayr 51 President, Intercontinental Operations (since
September 1997)*
Richard D. Pilnik 41 Vice President, Strategy and Marketing (since January
1998)*
Robert N. Postlethwait 49 President, Neuroscience Business Unit (since August
1994)*
William R. Ringo, Jr. 52 President, Internal Medicine Business Unit (since
January 1998)*
Gino Santini 41 President, Women's Health Business Unit (since August
1997)*
Thomas Trainer 51 Vice President, Information Technology, and Chief
Information Officer (since January 1995)*
Albertus Van den Bergh 44 President, European Operations (since September 1997)*
</TABLE>
EMPLOYEES
At the end of 1997, the Company had approximately 31,100 employees,
including approximately 15,100 employees outside the United States. A
substantial number of the Company's employees have long records of continuous
service.
FINANCIAL INFORMATION RELATING TO FOREIGN AND DOMESTIC OPERATIONS
Financial information relating to foreign and domestic operations, set
forth in the Company's 1997 Annual Report at pages 32-33 under "Segment
Information" (pages 14-15 of Exhibit 13), is incorporated herein by reference.
Eli Lilly International Corporation, a subsidiary, coordinates the
Company's manufacture and sale of products outside the United States.
Local restrictions on the transfer of funds from branches and subsidiaries
located abroad (including the availability of dollar exchange) have not to date
been a significant deterrent in the Company's overall operations abroad. The
Company cannot predict what effect these restrictions or the other risks
inherent in foreign operations, including possible nationalization, might have
on its future operations or what other restrictions may be imposed in the
future. In addition, changing currency values can either favorably or
unfavorably affect the financial position and results of operations of the
Company. The Company actively manages its foreign exchange risk through various
hedging techniques including the use of foreign currency contracts.
- ----------
* Serves in office until successor is appointed.
-9-
<PAGE>
<PAGE>
ITEM 2. PROPERTIES
The Company's principal domestic and international executive offices are
located in Indianapolis. At December 31, 1997, the Company owned 14 production
and distribution facilities in the United States and Puerto Rico. Together with
the corporate administrative offices, these facilities contain an aggregate of
approximately 9.5 million square feet of floor area. Major production sites
include Indianapolis; Clinton and Lafayette, Indiana; and Carolina and Mayaguez,
Puerto Rico. The Company also leases sales offices in a number of cities located
in the United States and abroad. PCS owns or leases administrative facilities in
Scottsdale, Arizona, containing an aggregate of approximately 480,000 square
feet, and leases a 94,000 square foot mail-order pharmacy facility in Fort
Worth, Texas. It also leases administrative space in other cities in the United
States. Integrated Medical Systems leases administrative space in a number of
locations.
The Company owns production and distribution facilities in 18 countries
outside the United States and Puerto Rico, containing an aggregate of
approximately 4.0 million square feet of floor space. Leased production and
warehouse facilities are utilized in Puerto Rico and 17 countries outside the
United States.
The Company's research and development facilities in the United States
consist of approximately 3.7 million square feet and are located primarily in
Indianapolis and Greenfield, Indiana. Its major research and development
facilities abroad are located in Belgium, Germany, and the United Kingdom and
contain approximately 387,000 square feet. The Company also owns two tracts of
land, containing an aggregate of approximately 1,700 acres, a portion of which
is used for field studies of products.
The Company believes that none of its properties is subject to any
encumbrance, easement, or other restriction that would detract materially from
its value or impair its use in the operation of the business of the Company. The
buildings owned by the Company are of varying ages and in good condition.
ITEM 3. LEGAL PROCEEDINGS
Prozac Patent Litigation. In March 1996 the Company was informed by Barr
Laboratories, Inc. ("Barr") that it had submitted an abbreviated new drug
application ("ANDA") to the U.S. FDA seeking to market a generic form of Prozac
in the United States several years before the expiration of the Company's
patents. Barr has alleged that the Company's U.S. patents covering Prozac are
invalid and unenforceable. On April 11, 1996, the Company filed suit in the
United States District Court for the Southern District of Indiana seeking a
ruling that Barr's challenge to the Company's patents is without merit. In the
second quarter of 1997, the Company was informed that Geneva Pharmaceuticals,
Inc. ("Geneva") had submitted a similar ANDA and, like Barr, had asserted that
the Company's U.S. Prozac patents are invalid and unenforceable. On June 23,
1997, the Company sued Geneva in the same court seeking a similar ruling as in
the Barr suit. The two suits have been consolidated and discovery is proceeding.
The compound patent expires in February 2001 and a patent for the process by
which Prozac operates expires in December 2003. These patents are material to
the Company. The Company believes that the claims of Barr and Geneva are without
merit and that the Company should be successful in this litigation. However, it
is not possible to predict or determine the outcome of this litigation and
accordingly there can be no assurance that the
-10-
<PAGE>
<PAGE>
Company will prevail. An unfavorable outcome could have a material adverse
effect on the Company's consolidated financial position, liquidity, or results
of operations.
Product Liability Litigation. The Company is currently a defendant in a
variety of product litigation matters involving primarily diethylstilbestrol
("DES") and Prozac. In approximately 170 actions, including several with
multiple claimants, plaintiffs seek to recover damages on behalf of children or
grandchildren of women who ingested DES during pregnancy. In another
approximately 15 actions, plaintiffs seek to recover damages as a result of the
ingestion of Prozac.
Pricing Litigation. The Company has been named, together with numerous
other U.S. prescription pharmaceutical manufacturers and in some cases
wholesalers or distributors, as a defendant in a large number of related actions
brought by retail pharmacies and consumers of prescription pharmaceuticals in
the United States alleging violations of federal or state antitrust laws, or
both, based on the practice of providing discounts or rebates to managed-care
organizations and certain other purchasers. The federal cases have been
consolidated or coordinated in the Northern District of Illinois as In re Brand
Name Prescription Drugs Antitrust Litigation (MDL No. 997).
The federal suits include a certified class action on behalf of a majority
of retail pharmacies in the United States (the "Federal Class Action"). The
class plaintiffs allege an industrywide agreement in violation of the Sherman
Act to deny favorable pricing on sales of brand-name prescription
pharmaceuticals to certain retail pharmacies in the United States. The other
federal suits, brought as individual claims by several thousand pharmacies,
allege price discrimination in violation of the Robinson-Patman Act as well as
Sherman Act claims. The suits seek treble damages and injunctive relief against
allegedly discriminatory pricing practices.
The Company and several other manufacturers have agreed to settle the
Federal Class Action and that settlement is now final. The settlement amount,
which is not material, was accrued by the Company in the fourth quarter of 1995.
In addition, in June 1997 the Company reached a confidential settlement with a
number of retail pharmacy and supermarket chains that were plaintiffs in the
federal actions but had opted out of the Federal Class Action. With respect to
the remaining Robinson-Patman Act claims, the District Court has designated
certain plaintiffs and defendants named in the individual suits (not including
the Company) to participate in an initial trial or trials of the claims. No
trial dates have been set. Robinson-Patman claims asserted in the suits against
nondesignated defendants, including the Company, are stayed.
In addition, there are a number of related state court cases. The state
court suits typically seek money damages and injunctive relief against allegedly
discriminatory pricing practices. Cases have been brought in Alabama,
California, Minnesota, Mississippi, and Wisconsin by retail pharmacies alleging
violations of various state antitrust and pricing laws, purporting to be class
actions on behalf of all retail pharmacies in those states. The court in
California has certified a class of retail pharmacies, while a Mississippi trial
court has denied class certification. Settlements have been reached and approved
by the trial courts in the Minnesota and Wisconsin cases. Cases have also been
brought in state courts in Alabama, Arizona, California, District of Columbia,
Florida, Kansas, Maine, Michigan, Minnesota, New York, North Carolina,
Tennessee, and Wisconsin that purport to be class actions on behalf of consumers
of prescription pharmaceuticals, alleging violations of state antitrust, pricing
or consumer protection laws. The courts in California and the District of
Columbia have certified
-11-
<PAGE>
<PAGE>
classes of consumer plaintiffs, while the Maine, Michigan, and Minnesota courts
have denied class certification. The New York case has been dismissed and an
appeal is pending.
Other Matters. In March 1996, the Federal Trade Commission ("FTC")
commenced a non-public investigation focusing on the pricing practices described
under "Pricing Litigation" above. The Company has responded to two subpoenas
from the FTC requesting production of certain documents and other discovery
responses. The Company believes that all of its actions have been lawful and
proper and is cooperating with the investigation.
In October 1996, the FTC issued a subpoena to the Company and PCS
requesting production of certain documents in connection with a non-public
investigation reviewing whether the relationships and activities between
pharmacy benefit management companies and pharmaceutical companies have violated
federal antitrust law, including a review of whether the Company has violated
the consent decree it entered into at the time it acquired PCS in 1994. The
Company believes that all its actions and those of PCS have been lawful, proper
and in compliance with the PCS consent decree. The Company and PCS are
cooperating with the FTC's investigation.
The Company is also a defendant in other litigation, including product
liability and patent suits, of a character regarded as normal to its business.
While it is not possible to predict or determine the outcome of the legal
actions and investigations pending against the Company, the Company believes
that except as noted above, the costs associated with all such matters will not
have a material adverse effect on its consolidated financial position or
liquidity but could possibly be material to the consolidated results of
operations in any one accounting period.
ITEM 4. SUBMISSION OF MATTERS TO A VOTE OF SECURITY
HOLDERS
During the fourth quarter of 1997, no matters were submitted to a vote of
security holders.
PART II
ITEM 5. MARKET FOR THE COMPANY'S COMMON STOCK AND RELATED STOCKHOLDER MATTERS
Information relating to the principal market for the Company's common stock
and related stockholder matters, set forth in the Company's 1997 Annual Report
under "Selected Quarterly Data (unaudited)," at page 34 (page 16 of Exhibit 13),
and "Selected Financial Data (unaudited)," at page 35 (page 17 of Exhibit 13),
is incorporated herein by reference.
ITEM 6. SELECTED FINANCIAL DATA
Selected financial data for each of the Company's five most recent fiscal
years, set forth in the Company's 1997 Annual Report under "Selected Financial
Data (unaudited)," at page 35 (page 17 of Exhibit 13), are incorporated herein
by reference.
-12-
<PAGE>
<PAGE>
ITEM 7. MANAGEMENT'S DISCUSSION AND ANALYSIS OF RESULTS OF
OPERATIONS AND FINANCIAL CONDITION
The following portions of the Company's 1997 Annual Report (found at pages
1-8 and 36-38 of Exhibit 13) constitute management's discussion and analysis of
results of operations and financial condition and are incorporated herein by
reference:
"Review of Operations--Stock split and per-share data"
(page 22)
"Review of Operations--Operating results and net income--1997"
(pages 22-25)
"Review of Operations--Operating results and net income--1996"
(pages 25-26)
"Review of Operations--Financial condition" (pages 26-27)
"Review of Operations--Environmental and legal matters" (pages 27 and 30)
"Review of Operations--Private Securities Litigation Reform Act of 1995 --
a caution concerning forward-looking statements" (page 30)
ITEM 7A. QUANTITATIVE AND QUALITATIVE DISCLOSURES ABOUT
MARKET RISK
Quantitative and qualitative disclosures about market risk (e.g., interest
rate risk and foreign currency exchange risk) are set forth in the Company's
1997 Annual Report at "Review of Operations--Financial Condition" at page 27
(pages 5-6 of Exhibit 13) and are incorporated by reference herein.
ITEM 8. FINANCIAL STATEMENTS AND SUPPLEMENTARY DATA
The consolidated financial statements of the Company and its subsidiaries,
listed in Item 14(a)1 and included in the Company's 1997 Annual Report at pages
24, 28, 29, and 31 (Consolidated Statements of Income, Consolidated Balance
Sheets, and Consolidated Statements of Cash Flows), pages 32 and 33 (Segment
Information), and pages 36-51 (Notes to Consolidated Financial Statements)
(together, pages 10-15 and 18-33 of Exhibit 13), and the Report of Independent
Auditors set forth in the Company's 1997 Annual Report at page 53 (page 35 of
Exhibit 13), are incorporated herein by reference.
Information on quarterly results of operations, set forth in the Company's
1997 Annual Report under "Selected Quarterly Data (unaudited)," at page 34 (page
16 of Exhibit 13), is incorporated herein by reference.
ITEM 9. DISAGREEMENTS ON ACCOUNTING AND FINANCIAL
DISCLOSURE
None.
-13-
<PAGE>
<PAGE>
PART III
ITEM 10. DIRECTORS AND EXECUTIVE OFFICERS OF THE REGISTRANT
Information relating to the Company's directors, set forth in the Company's
Proxy Statement dated March 4, 1998 (the "Proxy Statement"), under "Item 1.
Election of Directors" at pages 3-6, is incorporated herein by reference.
Information relating to the Company's executive officers is set forth at pages
7-9 of this Form 10-K under "Executive Officers of the Company." Information
relating to certain filing obligations of directors and executive officers under
the federal securities laws, set forth in the Proxy Statement under "Other
Matters--Section 16(a) Beneficial Ownership Reporting Compliance" at page 25,
is also incorporated herein by reference.
ITEM 11. EXECUTIVE COMPENSATION
Information relating to executive compensation, set forth in the Proxy
Statement under "Directors' Compensation", "Executive Compensation",
"Compensation Committee Interlocks", "Retirement Plan", and "Change-in-Control
Severance Pay Arrangements" at pages 9-18, is incorporated herein by reference,
except that the Compensation and Management Development Committee Report and
Performance Graph are not so incorporated.
ITEM 12. SECURITY OWNERSHIP OF CERTAIN BENEFICIAL OWNERS
AND MANAGEMENT
Information relating to ownership of the Company's common stock by persons
known by the Company to be the beneficial owners of more than 5% of the
outstanding shares of common stock and by management, set forth in the Proxy
Statement under "Common Stock Ownership by Directors and Executive Officers," at
page 8, and "Principal Holders of Common Stock," at page 9, is incorporated
herein by reference.
ITEM 13. CERTAIN RELATIONSHIPS AND RELATED TRANSACTIONS
The information in the Proxy Statement entitled "Certain Business
Relationships" at page 18 is incorporated herein by reference.
PART IV
ITEM 14. EXHIBITS, FINANCIAL STATEMENT SCHEDULES, AND REPORTS
ON FORM 8-K
(a)1. FINANCIAL STATEMENTS
The following consolidated financial statements of the Company and its
subsidiaries, included in the Company's 1997 Annual Report at the pages
indicated in parentheses, are incorporated by reference in Item 8:
Consolidated Statements of Income--Years Ended December 31, 1997, 1996,
and 1995 (page 24)(page 10 of Exhibit 13)
-14-
<PAGE>
<PAGE>
Consolidated Balance Sheets--December 31, 1997 and 1996 (pages 28-29)
(pages 11-12 of Exhibit 13)
Consolidated Statements of Cash Flows--Years Ended December 31, 1997,
1996, and 1995 (page 31)(page 13 of Exhibit 13)
Segment Information (pages 32-33)(pages 14-15 of Exhibit 13)
Notes to Consolidated Financial Statements (pages 36-51)(pages 18-33
of Exhibit 13)
(a)2. FINANCIAL STATEMENT SCHEDULES
The consolidated financial statement schedules of the Company and its
subsidiaries have been omitted because they are not required, are inapplicable,
or are adequately explained in the financial statements.
Financial statements of interests of 50% or less, which are accounted for
by the equity method, have been omitted because they do not, considered in the
aggregate as a single subsidiary, constitute a significant subsidiary.
(a)3. EXHIBITS
3.1 Amended Articles of Incorporation
3.2 By-laws
4.1 Rights Agreement dated as of July 18, 1988, between Eli Lilly and
Company and Bank One, Indianapolis, NA
4.2 Form of Indenture dated as of February 21, 1989, between Eli
Lilly and Company and Merchants National Bank & Trust Company of
Indianapolis, as Trustee
4.3 Form of Eli Lilly and Company Five Year Convertible Note
4.4 Form of Indenture with respect to Debt Securities dated as of
February 1, 1991, between Eli Lilly and Company and Citibank,
N.A., as Trustee
4.5 Form of Standard Multiple-Series Indenture Provisions dated, and
filed with the Securities and Exchange Commission on, February 1,
1991
4.6 Form of Fiscal and Paying Agency Agreement dated July 8, 1993,
between Eli Lilly and Company and Citibank, N.A., Fiscal and
Paying Agent, including forms of Notes, relating to 5-1/2% Notes
Due 1998 (1)
4.7 Form of Fiscal and Paying Agency Agreement dated February 7,
1995, between Eli Lilly and Company and Citibank, N.A., Fiscal
and Paying Agent, including forms of Notes, relating to 8-1/8%
Notes Due February 7, 2000(1)
- ----------
(1) These exhibits are not filed with this Report. Copies will be furnished to
the Securities and Exchange Commission upon request.
-15-
<PAGE>
<PAGE>
4.8 Form of Fiscal and Paying Agency Agreement dated February 7,
1995, between Eli Lilly and Company and Citibank, N.A., Fiscal
and Paying Agent, including forms of Notes, relating to 8-3/8%
Notes Due February 7, 2005 (1)
10.1 1984 Lilly Stock Plan, as amended (2)
10.2 1989 Lilly Stock Plan, as amended (2)
10.3 1994 Lilly Stock Plan, as amended (2)
10.4 The Lilly Deferred Compensation Plan, as amended (2)
10.5 The Lilly Directors' Deferral Plan, as amended (2)
10.6 The Eli Lilly and Company EVA'r'Bonus Plan, as amended (2),
(3)
10.7 Eli Lilly and Company Change in Control Severance Pay Plan for
Select Employees (2)
12. Computation of Ratio of Earnings to Fixed Charges
13. Annual Report to Shareholders for the Year Ended December 31,
1997 (portions incorporated by reference into this Form 10-K)
21. List of Subsidiaries
23. Consent of Independent Auditors
27.1 Financial Data Schedule
27.2- Restated Financial Data Schedules for Years ended December 31,
27.9 1995 and 1996 and Periods ended March 31, 1996 and 1997,
June 30, 1996 and 1997, and September 30, 1996 and 1997
99. Cautionary Statement under Private Securities Litigation Reform
Act of 1995--"Safe Harbor" for Forward-Looking Disclosures
(b) REPORTS ON FORM 8-K
The Company filed no reports on Form 8-K during the fourth quarter of 1997.
- ----------
(1) This exhibit is not filed with this Report. Copies will be furnished to
the Securities and Exchange Commission upon request.
(2) Indicates management contract or compensatory plan.
(3) EVA'r' is a registered trademark of Stern Stewart & Co.
-16-
<PAGE>
<PAGE>
SIGNATURES
Pursuant to the requirements of Section 13 or 15(d) of the Securities
Exchange Act of 1934, the Registrant has duly caused this report to be signed on
its behalf by the undersigned thereunto duly authorized.
ELI LILLY AND COMPANY
By s/Randall L. Tobias
_______________________________________
(Randall L. Tobias, Chairman of the Board
and Chief Executive Officer)
March 19, 1998
Pursuant to the requirements of the Securities Exchange Act of 1934,
this report has been signed below on March 19, 1998 by the following persons on
behalf of the Registrant and in the capacities indicated.
<TABLE>
<CAPTION>
SIGNATURE TITLE
- --------------------------------------------------------------------------------------------
<S> <C>
s/Randall L. Tobias Chairman of the Board, Chief Executive Officer,
__________________________________ and a Director (principal executive officer)
(RANDALL L. TOBIAS)
s/Charles E. Golden Executive Vice President, Chief Financial Officer,
__________________________________ and a Director (principal financial officer)
(CHARLES E. GOLDEN)
s/Arnold C. Hanish Chief Accounting Officer
__________________________________ (principal accounting officer)
(ARNOLD C. HANISH)
s/Evan Bayh Director
__________________________________
(EVAN BAYH)
s/Steven C. Beering, M.D. Director
__________________________________
(STEVEN C. BEERING, M.D.)
s/Karen N. Horn Director
__________________________________
(KAREN N. HORN, Ph.D.)
</TABLE>
-17-
<PAGE>
<PAGE>
<TABLE>
<CAPTION>
SIGNATURE TITLE
- --------------------------------------------------------------------------------------------
<S> <C>
s/Alfred G. Gilman, M.D., Ph.D. Director
__________________________________
(ALFRED G. GILMAN, M.D., Ph.D.)
s/J. Clayburn La Force, Jr., Ph.D. Director
__________________________________
(J. CLAYBURN LA FORCE, JR., Ph.D.)
s/Kenneth L. Lay, Ph.D. Director
__________________________________
(KENNETH L. LAY, Ph.D.)
s/Franklyn G. Prendergast, M.D., Ph.D. Director
______________________________________
(FRANKLYN G. PRENDERGAST, M.D., Ph.D.)
s/Kathi P. Seifert Director
__________________________________
(KATHI P. SEIFERT)
s/Sidney Taurel Director
__________________________________
(SIDNEY TAUREL)
s/August M. Watanabe, M.D. Director
__________________________________
(AUGUST M. WATANABE, M.D.)
s/Alva O. Way Director
__________________________________
(ALVA O. WAY)
</TABLE>
-18-
<PAGE>
<PAGE>
TRADEMARKS USED IN THIS REPORT
Trademarks or service marks owned by Eli Lilly and Company or its
subsidiaries or affiliates, when first used in this Report, appear with an
initial capital and are followed by the symbol 'r' or 'tm', as applicable. In
subsequent uses of the marks in the Report, the symbols are omitted.
<PAGE>
<PAGE>
INDEX TO EXHIBITS
The following documents are filed as part of this report:
<TABLE>
<CAPTION>
Exhibit Location
- ------- --------
<C> <S> <C>
3.1 Amended Articles of Incorporation Incorporated by reference from Exhibit
3.1 to the Company's Report on Form 10-Q
for the quarter ended March 31, 1996
3.2 By-laws Incorporated by reference from Exhibit 3
to the Company's Report on Form 10-Q for
the quarter ended September 30, 1997
4.1 Rights Agreement dated as of July 18, 1988, Incorporated by reference from Exhibit
between Eli Lilly and Company and Bank 4.11 to the Company's Report on Form
One, Indianapolis, N.A. 10-K for the fiscal year ended December
31, 1993
4.2 Form of Indenture dated as of February 21, Incorporated by reference from Exhibit
1989, between Eli Lilly and Company and 4.3 to the Company's Report on Form 10-K
Merchants National Bank & Trust Company for the fiscal year ended December 31,
of Indianapolis, as Trustee 1994
4.3 Form of Eli Lilly and Company Five Year Incorporated by reference from Exhibit
Convertible Note 4.4 to the Company's Report on Form 10-K
for the fiscal year ended December 31,
1994
4.4 Form of Indenture with respect to Debt Incorporated by reference from Exhibit
Securities dated as of February 1, 1991, 4.1 to the Company's Registration
between Eli Lilly and Company and Statement on Form S-3, Registration No.
Citibank, N.A., as Trustee 33-38347
4.5 Form of Standard Multiple-Series Indenture Incorporated by reference from Exhibit
Provisions dated, and filed with the 4.2 to the Company's Registration
Securities and Exchange Commission on Statement on Form S-3, Registration No.
February 1, 1991 33-38347
</TABLE>
<PAGE>
<PAGE>
<TABLE>
<CAPTION>
Exhibit Location
- ------- --------
<C> <S> <C>
4.6 Form of Fiscal and Paying Agency *
Agreement dated July 8, 1993, between Eli
Lilly and Company and Citibank, N.A.,
Fiscal and Paying Agent, including forms of
Notes, relating to 5-1/2% Notes Due 1998
4.7 Form of Fiscal and Paying Agency *
Agreement dated February 7, 1995, between
Eli Lilly and Company and Citibank, N.A.,
Fiscal and Paying Agent, including forms of
Notes, relating to 8-1/8% Notes Due
February 7, 2000
4.8 Form of Fiscal and Paying Agency *
Agreement dated February 7, 1995, between
Eli Lilly and Company and Citibank, N.A.,
Fiscal and Paying Agent, including forms of
Notes, relating to 8-3/8% Notes Due
February 7, 2005
10.1 1984 Lilly Stock Plan, as amended Incorporated by reference from Exhibit
10.1 to the Company's Report on Form
10-K for the fiscal year ended December
31, 1994
10.2 1989 Lilly Stock Plan, as amended Incorporated by reference from Exhibit
10.2 to the Company's Report on Form
10-K for the fiscal year ended December
31, 1993
10.3 1994 Lilly Stock Plan, as amended Incorporated by reference from Exhibit
10 to the Company's Report on Form 10-Q
for the quarter ended September 30, 1996
10.4 The Lilly Deferred Compensation Plan, as Incorporated by reference from Exhibit
amended 10.4 to the Company's Report on Form
10-K for the fiscal year ended December
31, 1994
</TABLE>
-2-
<PAGE>
<PAGE>
<TABLE>
<CAPTION>
Exhibit Location
- ------- --------
<C> <S> <C>
10.5 The Lilly Directors' Deferral Plan, as amended Incorporated by reference from Exhibit
10.5 to the Company's Report on Form
10-K for the fiscal year ended December
31, 1996
10.6 The Eli Lilly and Company EVA'r' Bonus Attached
Plan, as amended
10.7 Eli Lilly and Company Change in Control Incorporated by reference from Exhibit
Severance Pay Plan for Select Employees 10 to the Company's Report on Form 10-Q
for the quarter ended March 31, 1995
12. Computation of Ratio of Earnings to Fixed Attached
Charges
13. Annual Report to Shareholders for the Year Attached
Ended December 31, 1997 (portions
incorporated by reference in this Form 10-K)
21. List of Subsidiaries Attached
23. Consent of Independent Auditors Attached
27.1 Financial Data Schedule Attached
27.2- Restated Financial Data Schedules Attached
27.9 for Years ended December 31, 1995 and
1996 and Periods ended March 31, 1996
and 1997, June 30, 1996 and 1997,
and September 30, 1996 and 1997
99. Cautionary Statement Under Private Attached
Securities Litigation Reform Act of 1995 --
"Safe Harbor" for Forward-Looking
Disclosures
</TABLE>
-3-
STATEMENT OF DIFFERENCES
The trademark symbol shall be expressed as................................'tm'
The registered trademark symbol shall be expressed as......................'r'
Characters normally expressed as subscript shall be expressed as baseline
characters.
<PAGE>
<PAGE>
ELI LILLY AND COMPANY EVA'r' BONUS PLAN
(As amended and restated effective January 1, 1998)
ARTICLE I
BONUS PLAN STATEMENT OF PURPOSE AND SUMMARY
1.1 The purpose of the Plan is to provide a system of bonus compensation for
selected employees of Eli Lilly and Company and subsidiaries which will
promote the maximization of shareholder value over the long term, by
linking performance incentives to increases in shareholder value. The Plan
ties bonus compensation to Economic Value Added ("EVA"), and thereby
rewards employees for long-term, sustained improvement in shareholder
value.
1.2 EVA will be used as the performance measure of value creation. EVA reflects
the benefits and costs of capital employment. Employees create economic
value when the operating profits from a business exceed the cost of the
capital employed.
ARTICLE II
DEFINITIONS OF CERTAIN TERMS
Unless the context requires a different meaning, the following terms shall have
the following meanings:
2.1 "Company" means Eli Lilly and Company and its subsidiaries.
2.2 "Committee" means the Compensation and Management Development Committee,
the members of which shall be selected by the Board of Directors from among
its members.
2.3 "Participant" means any employee of the Company designated by the Committee
as a participant in the Plan with respect to any Plan Year. In its
discretion, the Committee may designate Participants either on an
individual basis or by determining that all employees in specified job
categories, classification or levels shall be Participants.
2.4 "Plan" means this Eli Lilly and Company EVA Bonus Plan.
2.5 "Plan Year" means the applicable calendar year.
2.6 "Retirement" means the cessation of employment upon the attainment of at
least eighty age and service points, as determined by the provisions of The
Lilly Retirement Plan as amended from time to time, assuming eligibility to
participate in that plan.
<PAGE>
<PAGE>
2.7 "Disability" means the time at which a Participant becomes eligible for a
payment under The Lilly Extended Disability Plan, assuming eligibility to
participate in that plan.
ARTICLE III
DEFINITION AND COMPONENTS OF EVA
The following terms set forth the calculation of EVA and the components of
calculating EVA. The calculation of EVA for a Plan Year is used in determining
the bonuses earned by Participants under the Plan, as set forth in Article IV.
3.1 "Economic Value Added" or "EVA" means the excess NOPAT that remains after
subtracting the Capital Charge.
3.2 "Net Operating Profit After Tax" or "NOPAT" means the after tax operating
earnings of the Company for the Plan Year. NOPAT is determined by adding
net sales plus other net income (excluding interest income from operating
cash) and subtracting the following: cost of goods sold, selling, general
and administrative expenses (excluding goodwill amortization and interest
expense), amortization of research and development, taxes (excluding the
tax benefit of interest expense) and amounts associated with discontinued
operations.
3.3 "Capital Charge" means the deemed opportunity cost of employing Capital for
the Company. The Capital Charge is calculated by multiplying Capital times
Cost of Capital (C*).
3.4 "Capital" means the net investment employed in the operations of the
Company produced by operations and financing activities. Capital is
calculated by adding together current assets (excluding operating cash),
net property, plant and equipment, gross goodwill, net intangibles, other
assets, and capitalized research and development, and the present value of
operating leases, and subtracting the following: non-interest bearing
liabilities and capital associated with discontinued operations.
3.5 "Cost of Capital" or "C*" is the percentage calculated from the weighted
average of Cost of Debt and Cost of Equity. Cost of Capital for each Plan
Year is determined by reference to the percentage calculated at the end of
October of the prior Plan Year.
3.6 "Cost of Debt" capital is the marginal long-term borrowing rate of the
Company times (one minus the tax rate).
3.7 "Cost of Equity" capital is the risk-free rate plus (beta times the market
risk premium). For this purpose, (i) "risk free rate" is the 30-year U.S.
Treasury Bond rate, (ii) "beta" represents the 5 year historical average
variation of the Company's earnings versus the S&P 500, and (iii) "market
risk premium" represents the average risk of an equity return versus a bond
return.
2
<PAGE>
<PAGE>
ARTICLE IV
DEFINITION AND COMPUTATION OF THE EVA BONUS
Bonuses earned under the Plan for a Plan Year are determined based on a
comparison of actual EVA to the "Target EVA" for the year, which is established
as described below to ensure improvement in EVA from year to year. The result of
this comparison is adjusted by a "Leverage Factor" measuring the volatility of
industry returns. The factor produced is referred to as the "Bonus Multiple,"
which is multiplied by the Participant's "Target Bonus" amount established for
the year to produce the actual bonus earned. This amount, referred to as the
"Declared Bonus," is credited to the Participant's "Bonus Bank" balance and paid
out in the manner provided below.
4.1 Target Bonus. The Target Bonus Awards will be determined by the Committee
on a basis that takes into consideration a Participant's salary grade
level, job responsibilities, as well as past and expected future job
performance. Target Bonus Awards are expressed as a percentage of annual
base salary as in effect on the first day of the Plan Year. If a
Participant moves from any salary grade level to a G-6 or above salary
grade level during a Plan Year, he/she will receive an award that is
pro-rated according to time based on the Target Bonus percentage and base
salary applicable to each such salary grade. The Target Bonus will be based
on the currency in which the highest portion of base pay is regularly paid.
The Committee shall determine the appropriate foreign exchange conversion
methodology in its discretion.
4.2 Declared Bonus. A Declared Bonus is the Target Bonus times the Bonus
Multiple.
4.3 Bonus Multiple. The Bonus Multiple is the difference (positive or negative)
between Actual EVA and Target EVA, divided by the Leverage Factor, plus
one.
4.4 Bonus Bank. All bonus payments are made from the Bonus Bank. Each
Participant's beginning Bonus Bank balance in his/her first year of
participation is zero. The Bonus Bank is increased or decreased for any
plan year by the amount of Declared Bonus. If the available Bonus Bank
balance is positive, the Participant will be paid from such balance up to
the Target Bonus amount, plus one third of any such balance that remains
after subtracting the Target Bonus from available Bonus Bank balance. If
the available Bonus Bank balance is negative, no payment will occur.
4.5 Target EVA. The Target EVA for each year will be calculated as follows:
Target EVA = [Prior Year's Actual EVA + Prior Year's Target EVA] + Expected
---------------------------------------------------
2 Improvement
4.6 Expected Improvement. The Expected Improvement is the additional EVA amount
determined by the Committee that is used to assure that a minimum level of
improvement is achieved in order to earn target awards.
4.7 Leverage Factor. The Leverage Factor determines the rate of change in
bonuses as EVA surpasses or falls short of Target EVA, determined by the
Committee from an evaluation of the long term volatility of industry
returns.
3
<PAGE>
<PAGE>
4.8 Working Plan Example. Examples of the mechanics of the Plan are shown on
Schedule A.
ARTICLE V
PLAN ADMINISTRATION
5.1 Time of Payment. Payment from the Bonus Bank will be made before March 1 of
the year following the Plan Year.
5.2 Certification of Results. Before any amount is paid under the Plan, the
Committee shall certify in writing the calculation of EVA for the Plan Year
and the satisfaction of all other material terms of the calculation of the
Declared Bonus.
5.3 New Hires, Promotions. New hires or individuals promoted who are first
selected for participation by the Committee effective on a date other than
January 1 will participate on a pro-rata basis in their first year of
participation, based on the Declared Bonus determined for the Plan Year,
pro-rated for that period of the year during which the Participant was
selected for participation in the Plan. Any such Participant's Target Bonus
Award will be determined based on his or her annual base salary as in
effect on the date of hire or promotion, as applicable.
5.4 Termination of Employment, Demotions. If a Participant ceases employment
with the Company before the end of a Plan Year for reasons other than
Retirement, Disability or death, or is demoted to a non-global job level
with the Company during a Plan Year, the Participant shall receive no
Declared Bonus for that Plan Year, and his/her Bank Balance shall be
forfeited. The Committee may make complete or partial exceptions to this
rule, in its sole discretion.
5.5 Leave of Absence. If a Participant takes an approved leave of absence from
employment during a Plan Year, the Participant will not be eligible for the
Declared Bonus for the Plan Year. The Committee may make complete or
partial exceptions to this rule, in whatever manner it deems appropriate.
The Participant will retain his Bonus Bank balance if he returns to
employment following the period of leave of absence.
5.6 Retirement, Disability or Death. If a Participant ceases employment with
the Company because of Retirement, Disability or death, the Participant or
personal representative, as the case may be, shall receive full payment of
his/her Bank Balance and a bonus based on the Declared Bonus determined for
the Plan Year but pro-rated for that period of the year during which the
Participant was an active employee of the Company.
5.7 Plan Participation. A Participant may not participate in this Plan for any
portion of a year for which he/she is entitled to receive payment under the
Eli Lilly and Company Contingent Compensation Plan, and shall be treated in
accordance with 5.3.
5.8 Forfeiture Events. Notwithstanding any other provision of this Plan to the
contrary, the Committee may, in its sole discretion, upon the occurrence of
a Forfeiture Event (as defined below), forfeit all or any portion of a
Participant's Declared Bonus and Bonus
4
<PAGE>
<PAGE>
Bank balance and terminate such Participant's future participation in the
Plan. For purposes hereof, a "Forfeiture Event" shall mean the occurrence
of one or more of the following events with respect to a Participant: (i)
the termination or forced resignation from employment of the Participant
for "misconduct" (as defined in the Company's Employee Information
Handbook), (ii) any violation by the Participant of the Guidelines of
Company Policy (the "Redbook") that is detrimental to the Company, (iii)
any breach of a noncompetition, nonsolicitation, nondisclosure or other
restrictive covenant that may apply by written agreement between the
Company and the Participant or (iv) Participant's having engaged in any
other activity that, in the judgment of the committee, is detrimental to
the business, affairs or reputation of the Company (including, without
limitation, engaging in any criminal activity).
ARTICLE VI
GENERAL PROVISIONS
6.1 Withholding of Taxes. The Company shall have the right to withhold the
amount of taxes which in the sole determination of the Company are required
to be withheld under law with respect to any amount due or payable under
the Plan.
6.2 Expenses. All expenses and costs in connection with the adoption and
administration of the plan shall be borne by the Company.
6.3 No Prior Right or Offer, No Right to Future Participation. Participation in
the Plan for Plan Years is determined from year-to-year by the Committee in
its sole discretion. Except and until expressly granted pursuant to the
Plan, nothing in the Plan shall be deemed to give any employee any
contractual or other right to participate in the benefits of the Plan. No
award to any such Participant in any Plan Year shall be deemed to create a
right to receive any award or to participate in the benefits of the Plan in
any subsequent Plan Year.
6.4 Rights Personal to Employee. Any rights provided to an employee under the
Plan shall be personal to such employee, shall not be transferable, except
by will or pursuant to the laws of descent or distribution, and shall be
exercisable during his/her lifetime, only by such employee, or a
court-appointed guardian for the employee.
6.5 Non-Allocation of Award. In the event of a suspension of the Plan in any
Plan Year, as described in Section 11.1, no awards under the Plan for the
Plan Year during which such suspension occurs shall affect the calculation
of awards for any subsequent period in which the Plan is continued.
ARTICLE VII
LIMITATIONS
7.1 No Continued Employment. Neither the establishment of the Plan nor the
grant of an award thereunder shall be deemed to constitute an express or
implied contract of
5
<PAGE>
<PAGE>
employment of any Participant for any period of time or in any way abridge
the rights of the Company to determine the terms and conditions of
employment or to terminate the employment of any employee with or without
notice or cause at any time.
7.2 No Vested Rights. Except as expressly provided herein, no employee or other
person shall have any claim of right (legal, equitable, or otherwise) to
any award, allocation, or distribution or any right, title, or vested
interest in any amounts in his/her Bonus Bank and no officer or employee of
the Company or any other person shall have any authority to make
representations or agreements to the contrary. No interest conferred herein
to a Participant shall be assignable or subject to claim by a Participant's
creditors.
7.3 Non-alienation. Except as provided in Subsection 5.1, no Participant or
other person shall have any right or power, by draft, assignment, or
otherwise, to mortgage, pledge or otherwise encumber in advance any payment
under the Plan, and every attempted draft, assignment, or other disposition
thereof shall be absolutely void.
ARTICLE VIII
COMMITTEE AUTHORITY
8.1 Authority to Interpret and Administer. Except as otherwise expressly
provided herein, full power and authority to interpret and administer this
Plan shall be vested in the Committee. The Committee may from time to time
make such decisions and adopt such rules and regulations for implementing
the Plan as it deems appropriate for any Participant under the Plan. Except
as to Participants who are treated by the Company as executive officers of
the Company for federal securities law reporting purposes, the Committee
may delegate in writing to officers or employees of the Company the power
and authority granted by this Section 8.1 to interpret and administer this
Plan. Any decision taken by the Committee or officer or employee to whom
authority has been delegated, arising out of or in connection with the
construction, administration, interpretation and effect of the Plan shall
be final, conclusive and binding upon all Participants and any person
claiming under or through Participants.
8.2 Committee Discretion to Revise Rates and Amounts. The committee may, in its
sole discretion, revise the various rates, amounts and percentages provided
in the Plan from time to time (including, without limitation, with respect
to each of the foregoing defined terms), provided that the methods and
assumptions used in making such determinations shall be established and
applied by the Committee on the basis of reasonable, objective criteria
that are applied in a uniform manner from Plan Year to Plan Year.
8.3 Financial And Accounting Terms. Except as otherwise provided, financial and
accounting terms, including terms defined herein, shall be determined by
the Committee in accordance with generally accepted accounting principles
and as derived from the audited consolidated financial statements of the
Company, prepared in the ordinary course of business.
6
<PAGE>
<PAGE>
ARTICLE IX
NOTICE
9.1 Any notice to be given to the Company or Committee pursuant to the
provisions of the Plan shall be in writing and directed to Secretary, Eli
Lilly and Company, Lilly Corporate Center, Indianapolis, IN 46285.
ARTICLE X
EFFECTIVE DATE
10.1 This Plan shall be effective as of January 1, 1995, as amended and restated
effective January 1, 1998.
ARTICLE XI
AMENDMENTS AND TERMINATION
11.1 This Plan may be amended, suspended or terminated at any time at the
discretion of the Board of Directors of Eli Lilly and Company, and may,
except for this Section 11.1, be amended at any time by the Committee.
ARTICLE XII
APPLICABLE LAW
12.1 This Plan shall be governed by and construed in accordance with the
provisions of the laws of the State of Indiana.
- ----------------
EVA'r' is a registered trademark of Stern Stewart & Co.
7
<PAGE>
<PAGE>
SCHEDULE A
Year One
Target EVA = $150MM
Actual EVA = $200MM
Leverage Factor = $100MM
[GRAPHIC]
Economic Value Added Grid
-------------------------
EVA Bonus Multiple
--- --------------
$250 MM 2.0
$200 MM 1.5
$150 MM 1.0
$ 50 MM 0
Declared Bonus
- --------------
Actual EVA - Target EVA = $50MM
Bonus Multiple = 1 + (Actual EVA - Target EVA)/ Leverage Factor
1.5 = 1 + 50/100
Target Bonus = $20,000
Declared Bonus = $30,000 (1.5 x $20,000)
Bonus Bank
- ----------
Declared Bonus $30,000
Beginning Bank Balance $0
-----------
Available Bank Balance $30,000
Target Bonus Paid $20,000*
------
Remaining Balance $10,000
Pay 1/3 Remaining Balance $3,333*
------
Ending Bank Balance $6,667
*Total bonus paid = $20,000 + $3,333 = $23,333
EVA Target Reset (for year two) = ($200MM + $150MM)/2 + 0
= $175MM
8
<PAGE>
<PAGE>
Schedule A (Cont.)
Year Two
Target EVA = $175MM
Actual EVA = $140MM
Leverage Factor = $100MM
[GRAPHIC]
Economic Value Added Grid
-------------------------
EVA Bonus Multiple
------- --------------
$275 MM 2.0
$175 MM 1.0
$140 MM 0.65
$ 75 MM 0
Declared Bonus
- --------------
Actual EVA - Target EVA = ($35MM)
Bonus Multiple = 1 + (Actual EVA - Target EVA)/ Leverage Factor
0.65 = 1 + (35)/100
Target Bonus = $20,000
Declared Bonus = $13,000 (0.65 x $20,000)
Bonus Bank
- ----------
Declared Bonus $13,000
Beginning Bank Balance $6,667
------
Available Bank Balance $19,667
Target Bonus Paid $19,667*
------
(up to available balance)
Remaining Balance $0
Pay 1/3 Remaining Balance $0*
---------
Ending Bank Balance $0
*Total bonus paid = $19,667 + $0 = $19,667
EVA Target Reset (for year three) = ($140MM + $175MM)/2 + 0
= $157.5MM
9
<PAGE>
<PAGE>
EXHIBIT 12. STATEMENT RE: COMPUTATION OF RATIO OF EARNINGS
FROM CONTINUING OPERATIONS TO FIXED CHARGES
(Dollars in Millions)
<TABLE>
<CAPTION>
Years Ended December 31,
--------------------------------------------------------------
1997 1996 1995 1994 1993
---- ---- ---- ---- ----
<S> <C> <C> <C> <C> <C>
Consolidated Pretax
Income from Continuing
Operations before
Accounting Changes.......... $ 510.2 $2,031.3 $1,765.6 $1,698.6 $ 662.8
Interest from Continuing
Operations and Other
Fixed Charges............... 260.0 324.9 324.6 129.2 96.1
Less Interest Capitalized
during the Period from
Continuing Operations....... (23.8) (36.1) (38.3) (25.4) (25.5)
-------- -------- ------- ------- --------
Earnings....................... $ 746.4 $2,320.1 $2,051.9 $1,802.4 $ 733.4
======= ======= ======= ======= =======
Fixed Charges(1)............... $ 264.2 $ 329.6 $ 324.6 $ 129.2 $ 96.1
======= ======= ======= ======= =======
Ratio of Earnings to
Fixed Charges............... 2.8(2) 7.0 6.3 14.0 7.6
=== === === ==== ===
</TABLE>
(1)Fixed charges include interest from continuing operations for all years
presented and beginning in 1996, preferred stock dividends.
(2)Included in the 1997 earnings is a noncash charge of $2,443 million due to
an asset impairment. See notes to consolidated financial statements. If the
asset impairment charge had not occurred, the ratio of earnings to fixed
charges would have been 12.1.
<PAGE>
<PAGE>
EXHIBIT 13. ANNUAL REPORT TO SHAREHOLDERS FOR THE YEAR
ENDED DECEMBER 31, 1997
REVIEW OF OPERATIONS
STOCK SPLIT AND PER-SHARE DATA
On September 15, 1997, the company's board of directors declared a two-for-one
stock split payable to shareholders of record on September 24, 1997. The
outstanding and weighted-average number of shares of common stock and per-share
data herein have been adjusted to reflect the impact of the stock split for all
periods presented. Treasury shares held by the company were not split.
In 1997, the company adopted Statement of Financial Accounting Standards (SFAS)
No. 128, "Earnings per Share," which requires presentation of both basic
earnings per share and diluted earnings per share in the income statement.
Further, the SFAS requires restatement of previously reported earnings-per-share
data. Unless otherwise noted, all per-share amounts are presented on a diluted
basis, that is, based on the weighted-average number of outstanding common
shares and the effect of all potentially dilutive common shares (primarily
unexercised stock options).
OPERATING RESULTS AND NET INCOME--1997
The company's operating results for both 1997 and 1996 reflect the impact of
several significant transactions that make comparisons difficult. The company's
reported results for 1997 include the following significant transactions: a $2.4
billion noncash charge to adjust the carrying value of the long-lived assets of
PCS' health-care-management businesses, a pretax gain of $631.8 million from the
sale of the company's interest in the DowElanco joint venture, a charge for the
settlement of a significant portion of the company's remaining retail pharmacy
pricing litigation and a $24 million charge for the discontinuance of the
research collaboration with Somatogen, Inc. The company's reported tax rate for
1997 was also affected by these transactions. As a consequence, 1997 reflected a
net loss of $385.1 million, or $.35 per share.
Excluding the significant items noted above, net income for 1997 would have been
$1.77 billion, or $1.57 per share. After excluding the income from the sale of
the U.S. marketing rights for Ceclor'r' CD and Keftab'r' to Dura
Pharmaceuticals, Inc., from the 1996 amounts, 1997 net income and earnings per
share, without the significant items, reflect increases from 1996 of 22 and 21
percent, respectively. The 1997 increases are attributed to increased sales,
improved gross margin, and reduced interest expense and goodwill, partially
offset by decreased other income.
The company's sales for 1997 increased 16 percent, to $8.52 billion. Sales in
the United States were $5.41 billion, a 27 percent increase, while sales outside
the United States were $3.11 billion, a 1 percent increase. Worldwide sales
volume growth of 18 percent and a 2 percent increase in global selling prices
were partially offset by unfavorable exchange rates, which decreased sales by 4
percent.
Worldwide pharmaceutical sales increased 17 percent, to $7.92 billion. The sales
growth was led by three of the company's newer products, Gemzar'r', ReoPro'r'
and Zyprexa'r', as well as increased sales of Prozac'r' and insulin products and
additional health-care-management revenues. The 1997 growth was achieved despite
lower sales of anti-infective products. Total U.S. pharmaceutical sales
increased 28 percent ($1.12 billion) primarily as a result of increased volume.
International pharmaceutical sales increased 1 percent. Sales volume growth
outside the U.S. of 12 percent was offset largely by unfavorable exchange rates
(9 percent) and decreased selling prices (2 percent).
Worldwide sales of the antidepressant Prozac in 1997 were $2.56 billion, an
increase of 9 percent. Prozac sales in the U.S. increased 17 percent, to $2.02
billion. International sales of Prozac experienced a decline of 14
1
<PAGE>
<PAGE>
percent due largely to the effects of unfavorable exchange rates, continuing
generic competition in Canada and competitive pressures in France. The company
expects moderate growth in worldwide Prozac sales in 1998.
Three of the company's newer products contributed significantly to the worldwide
pharmaceutical sales growth. Specifically, in 1997, Zyprexa, a treatment for
schizophrenia and related psychoses launched in the fourth quarter of 1996,
contributed $730.2 million to worldwide sales and $590.0 million to U.S. sales,
which represent increases of $643.3 million and $511.7 million, respectively.
ReoPro, a cardiovascular product launched in 1995, reported worldwide sales of
$254.4 million, reflecting an increase of $105.1 million. U.S. ReoPro sales
increased $85.6 million, to $218.6 million. Worldwide sales of Gemzar, an
oncolytic launched in the U.S. in May 1996, grew to $174.8 million, representing
an increase over 1996 of $113.0 million. Gemzar sales in the U.S. increased
$63.4 million, to $95.0 million.
Among other major products, worldwide sales of Humulin'r', the company's
biosynthetic human insulin, increased 6 percent, to $936.0 million, for 1997.
U.S. Humulin sales increased 4 percent, to $586.8 million, with growth due to
wholesaler buying patterns being offset partially by the combined effect of
competition from oral antidiabetic agents and increased sales of the company's
insulin analog, Humalog'r'. International Humulin sales increased 9 percent. In
addition, health-care-management revenues increased 47 percent, to $548.5
million, largely due to increased mail order pharmacy sales. Worldwide sales of
the antiulcer agent Axid'r' decreased 1 percent, to $526.5 million. Axid sales
declined 2 percent in the U.S. and increased 3 percent outside the U.S.
Worldwide sales of the human growth hormone Humatrope declined 3 percent.
Compared with 1996, worldwide anti-infective sales in 1997 decreased $178.9
million (12 percent). This decline was due primarily to continued generic
competition in certain markets and the impact of unfavorable exchange rates.
Sales of the oral antibiotic cefaclor decreased 18 percent, to $442.2 million,
accounting for the majority of this decline. Both U.S. and international
anti-infectives sales reflected declines. The company anticipates that 1998
worldwide sales of anti-infectives will be below 1997 levels largely due to
continued pricing pressures as a result of generic competition.
The company's payments under federally mandated Medicaid rebate programs reduced
1997 sales by approximately $200 million. The company anticipates that rebates
associated with Medicaid rebate programs will increase in 1998.
Worldwide sales of animal health products increased 8 percent over 1996, driven
by volume growth of 10 percent. Sales increased 15 percent in the U.S. and 2
percent outside the U.S. The worldwide sales increase was primarily due to
increased sales of Micotil'r', an antibiotic for bovine respiratory disease, and
Tylan'r', an antibiotic for promoting feed efficiency and growth in swine and
cattle.
Gross margin improved to 72.3 percent of sales compared with 71.2 percent for
1996. This increase was primarily the result of favorable pharmaceutical product
mix, production efficiencies and procurement savings. These improvements were
offset, in part, by increased health-care-management revenues, which have lower
margins than pharmaceutical products. The company anticipates that the gross
margin percentage will increase slightly in 1998 due largely to continued
improvement in pharmaceutical product mix.
Research and development expenses in 1997 increased 16 percent. Expenses in
support of global clinical trials, as well as an increase in external research
collaborations relating to the discovery and development of new technologies,
compounds and delivery systems, drove this increase. The company expects
spending in research and development to increase at a greater rate during 1998
and likely at a rate above that of sales growth. The actual 1998 increase will
vary depending upon a number of factors, particularly the level of research
collaboration activity.
Marketing and administrative expenses increased 16 percent over 1996. Overall,
the increase was largely due to increased expenditures to support continued new
product launches around the world, including the January 1998 launch of
Evista'r', a product for the prevention of osteoporosis; the Prozac
2
<PAGE>
<PAGE>
direct-to-consumer advertising campaign; enhancements of the company's global
information technology capabilities; and increased compensation accruals due to
the company's performance-based bonus programs. The charge for the settlement of
a significant portion of the company's remaining retail pharmacy pricing
litigation also contributed to the 1997 increase. Excluding that charge,
marketing and administrative expenses would have increased at a rate below that
of sales.
Many of the company's computer systems will require modification or replacement
over the next two years in order to render the systems ready for the year 2000.
Key information, financial, research and operational systems have been assessed
and plans have been formulated to address system modifications required by
December 31, 1999. Systems deemed most critical will be addressed in 1998; all
others are expected to be modified or replaced in 1999. Modifications of some
systems have already occurred. The company is also assessing how it could be
affected by the failure of third parties (e.g., vendors and customers) to
mitigate their own Year 2000 issues. The company will utilize both internal and
external resources to reprogram, or replace, and test the software for Year 2000
modifications. Expenses associated with addressing the Year 2000 issues are
being recognized as incurred. Although it is difficult to estimate future costs
precisely, management currently believes that the incremental costs of
addressing these issues will not materially affect the company's consolidated
financial position, liquidity or results of operations through December 31,
1999. The company believes it will be able to resolve all major Year 2000
issues. However, if the company is not able to do so, the impact on business
operations could be material to the company's consolidated results of
operations.
The asset impairment represents a noncash charge of approximately $2.4 billion
($2.21 per share), recorded in the second quarter of 1997, to adjust the
carrying value of PCS health-care-management businesses' long-lived assets,
primarily goodwill, to their fair value of approximately $1.5 billion. While
revenues and profits are growing and new capabilities are being developed at
PCS, the rapidly changing, competitive and highly regulated environment in which
PCS operates has prevented the company from significantly increasing PCS'
operating profits from levels that existed prior to the acquisition. In
addition, since the acquisition, the health-care-industry trend toward highly
managed care has been slower than originally expected and the possibility of
selling a portion of PCS' equity to a strategic partner has not been realized.
Therefore, in the second quarter, concurrent with PCS' annual planning process,
the company determined that PCS' estimated future undiscounted cash flows were
below the carrying value of PCS' long-lived assets. As a consequence, the
carrying value was adjusted to estimated fair value based on anticipated future
cash flows, discounted at a rate commensurate with the risk involved.
On June 30, 1997, The Dow Chemical Company acquired the company's 40 percent
interest in the DowElanco joint venture. The cash purchase price was $1.2
billion, resulting in an after-tax gain of $303.5 million, or $.28 per share.
Interest expense in 1997 decreased $54.7 million (19 percent) due primarily to a
decline in the company's borrowings.
Net other income for 1997 amounted to $97.2 million, which was $176.1 million
lower than in 1996. The decrease was primarily the result of several
nonrecurring items reflected in the 1996 amount, including the sale of the U.S.
marketing rights for Ceclor CD and Keftab (approximately $100 million), income
from codevelopment and comarketing contracts, the sale of marketing rights for
ReoPro in Japan and Tapazole'r' in the U.S., and a higher level of sales of
certain equity securities held by the company. Net other income for 1997
benefited by reduced goodwill amortization as a result of the asset impairment
and income from outlicensing activity. These increases were partially offset by
the charge for the discontinuance of the collaboration with Somatogen, Inc.
The company's reported tax rate for 1997 reflects the effects of the significant
transactions that occurred during the year. The company's tax rate, excluding
the impact of these items, was 25.0 percent, the same as the
3
<PAGE>
<PAGE>
tax rate for 1996. The company expects to sustain a comparable effective tax
rate for 1998.
OPERATING RESULTS AND NET INCOME--1996
Income from continuing operations in 1996 was $1.52 billion, or $1.36 per share,
which represents increases of 17 percent and 20 percent, respectively, from
1995. These increases reflect the favorable effects of increased sales and other
income and a lower effective tax rate, offset, in part, by reduced gross margins
and higher operating expenses. Earnings per share from continuing operations
also benefited from a reduced average number of shares of stock outstanding as a
result of the Guidant splitoff. Reported net income and earnings per share for
1996 include the impact of the sale of the U.S. marketing rights for Ceclor CD
and Keftab. Excluding this transaction, 1996 net income and earnings per share
would have been $1.45 billion and $1.30, respectively.
In 1995, the company completed the divestiture of all its Medical Devices and
Diagnostics (MDD) Division subsidiaries, realizing a net gain of $922 million.
This gain and the results of operations of MDD through the date of divestiture
added $984 million ($.86 per share) to net income in 1995. Reported net income
and earnings per share in 1996 do not include income from discontinued
operations.
Worldwide sales rose 9 percent in 1996, to $7.35 billion. An 11 percent growth
in unit volume was partially offset by foreign exchange rates and selling
prices, each of which decreased sales by 1 percent.
Sales in the United States in 1996 were $4.27 billion, a 12 percent increase.
Sales outside the United States were $3.08 billion, an increase of 4 percent
from 1995.
Pharmaceutical sales for 1996 increased 9 percent, to $6.79 billion, led by
Prozac (up $290 million, or 14 percent). Prozac sales increased despite
continuing competition from generics in Australia and Canada and competitive
pressures in France. Other products contributing significantly to the worldwide
pharmaceutical sales growth included Humulin (up 11 percent, to $884 million)
and three of the company's newer products, Gemzar, ReoPro and Zyprexa. Gemzar,
launched in the U.S. in May 1996, contributed $62 million to sales, and sales of
ReoPro increased $127 million over 1995. Zyprexa had a very strong first three
months after its October launch with sales of $87 million. The company's sales
also benefited from increased health-care-management revenues, which rose $112
million. The pharmaceutical sales growth for the year was partially offset by a
reduction in worldwide anti-infectives sales, discussed further below, and
slightly lower sales of Axid (down 3 percent) as a result of increased
competitive pressures.
Worldwide anti-infectives sales of $1.5 billion reflected a 13 percent decline.
In the U.S., the company experienced a decline of 37 percent due largely to
continued generic competition. Sales of anti-infectives outside the U.S.
reflected a 2 percent decline compared with 1995. The primary contributor to
this worldwide decline was cefaclor, which experienced a decrease in sales of 25
percent. All the company's other anti-infective products, except Dynabac'r',
experienced declines in the U.S. due to competition from both generic products
and newer branded products.
Pharmaceutical sales in the United States increased 12 percent, to $4.02
billion, all due to increased volume. Major products contributing to this growth
were Humulin (up $37 million), Prozac (up $292 million), ReoPro (up $112
million) and Zyprexa, which had U.S. sales of $78 million. Also, Gemzar
contributed $32 million in U.S. sales. This growth was offset, in part, by the
decline in anti-infectives sales and an increase in Medicaid rebates.
Pharmaceutical sales outside the U.S. increased 4 percent, to nearly $2.77
billion. The increase reflects volume growth of 10 percent offset, in part, by
price decreases and the negative effects of exchange rates. Major products
contributing to this increase were Gemzar, Humulin, Permax'r' and ReoPro. These
sales increases were partially offset by declines in anti-infectives and Axid.
4
<PAGE>
<PAGE>
Increases in Prozac sales achieved in most countries outside the U.S. were more
than offset by declines in certain countries, primarily Australia, Canada and
France.
Worldwide sales of animal health products increased 7 percent, to $547 million.
Sales increased 10 percent outside the U.S. and 3 percent in the U.S. The
worldwide sales increase occurred across a majority of the product line.
Gross margin was 71.2 percent of sales for 1996 compared with 72.1 percent in
1995. This decline primarily reflects the impact of increased
health-care-management revenues and reduced production volumes of certain
products as the company endeavors to reduce inventory levels (which resulted in
greater amounts of overhead costs being charged against income). These decreases
were partially offset by productivity improvements and an improved
pharmaceutical sales mix.
Research and development expenses increased 14 percent in support of global
clinical trials and an increase in external research collaborations.
Marketing and administrative expenses increased 7 percent. Overall, marketing
and administrative expenses increased largely due to costs associated with the
launches of the company's new products, continued efforts to expand globally,
the development of enhanced information technology capabilities, and increased
compensation accruals due to the company's performance-based bonus programs.
Interest expense of $289 million was approximately the same as in 1995. Net
other income of $273 million was $203 million higher than 1995. The increase was
primarily the result of several nonrecurring items, including the sale of the
U.S. marketing rights for Ceclor CD and Keftab; income from royalty,
codevelopment and comarketing contracts; the sale of marketing rights for ReoPro
in Japan and Tapazole in the U.S.; and gains from the sale of certain equity
securities.
The effective tax rate for 1996 was 25 percent compared with 26 percent in 1995.
The decline was primarily the result of changes in the mix of earnings between
jurisdictions having lower tax rates compared with those having higher rates and
the effectiveness of various tax-planning strategies.
FINANCIAL CONDITION
As of December 31, 1997, cash, cash equivalents and short-term investments
totaled approximately $2.02 billion compared with $955 million at December 31,
1996. Total debt at December 31, 1997, was $2.55 billion, a decrease of $1.18
billion. These improvements in cash, cash equivalents, short-term investments
and debt are primarily due to positive operating cash flows and the proceeds
from the sale of DowElanco, a portion of which was used to pay down short-term
borrowings (primarily commercial paper). The company believes that cash
generated from operations, along with available cash and cash equivalents, will
be sufficient to fund essentially all the company's operating needs, including
debt service, capital expenditures and dividends in 1998.
The company believes that amounts available through existing commercial paper
programs should be adequate to fund maturities of short-term borrowings. The
outstanding commercial paper is also backed by $2 billion of committed bank
credit facilities.
Following the company's announcement in June 1997 of the noncash charge for the
PCS asset impairment, the credit rating agencies affirmed the company's existing
commercial paper ratings (A1+ rating by Standard & Poor's, Prime-1 rating by
Moody's) and long-term debt ratings (AA rating by Standard & Poor's, Aa3 rating
by Moody's).
In the normal course of business, operations of the company are exposed to
fluctuations in currency values and interest rates. These fluctuations can vary
the costs of financing, investing and operating. The company addresses a portion
of these risks through a controlled program of risk management that includes the
use of derivative financial instruments. The objective of
5
<PAGE>
<PAGE>
controlling these risks is to limit the impact on earnings of fluctuations in
interest and currency exchange rates. All derivative activities are for purposes
other than trading.
The company's primary interest rate risk exposure results from changes in
short-term U.S. dollar interest rates. In an effort to manage interest rate
exposures, the company strives to achieve an acceptable balance between fixed
and floating rate debt positions and may enter into interest rate swaps to help
maintain that balance. Based on the company's overall interest rate exposure at
December 31, 1997, including derivatives and other interest rate sensitive
instruments, a hypothetical 10 percent change in interest rates applied to the
fair value of the instruments as of December 31, 1997, would have no material
impact on earnings, cash flows or fair values of interest rate risk sensitive
instruments over a one-year period.
The company's foreign currency risk exposure results from fluctuating currency
exchange rates, primarily the strengthening of the U.S. dollar against the
Japanese yen and European currencies. The company faces transactional currency
exposures that arise when its foreign subsidiaries (or the company itself) enter
into transactions, generally on an intercompany basis, denominated in currencies
other than their local currency. The company also faces currency exposure that
arises from translating the results of its global operations to the U.S. dollar
at exchange rates that have fluctuated from the beginning of the period. The
company uses forward contracts and purchased options to manage its foreign
currency exposures. Company policy outlines the minimum and maximum hedge
coverage of such exposures. Gains and losses on these derivative positions
offset, in part, the impact of currency fluctuations on the existing assets,
liabilities, commitments and anticipated revenues. Considering the company's
derivative financial instruments outstanding at December 31, 1997, a
hypothetical 10 percent weakening in the exchange rates (primarily the U.S.
dollar) over a one-year period would decrease earnings by $51.0 million while a
10 percent strengthening in the exchange rates would increase earnings by $67.8
million. This calculation does not reflect the impact of exchange gains/losses
on the underlying positions that would be offset, in part, by the results of the
derivative instruments.
In 1997, a subsidiary of the company issued $160 million (160 shares) of
convertible Class B stock to an institutional investor. The stock pays dividends
on a quarterly basis and is convertible at any time on a one-to-one basis into
the subsidiary's Class A stock at the option of the holder. The Class B stock
may be redeemed for $1 million per share plus accrued and unpaid dividends by
the subsidiary at specified periods or upon various redemption events or at the
option of the holder seven years from the date of issuance.
During 1997, the company continued to implement previously announced
restructuring and streamlining initiatives. Of these charges, approximately $31
million and $33 million were paid in cash in 1997 and 1996, respectively.
Charges yet to be paid in cash total approximately $125 million and are expected
to be funded from operations primarily over the next few years.
Capital expenditures of $366.3 million during 1997 were $77.6 million less than
in 1996 as construction was completed on new manufacturing, research and
development facilities early in 1997. The company expects near-term capital
expenditures to increase from 1997 levels but to remain well below the
historical peaks of the early 1990s. Sufficient cash flows exist to meet these
near-term requirements.
In the fourth quarter of 1997, the quarterly dividend was increased $.02 per
share (11 percent), which was the second increase in dividends for 1997 compared
with 1996. As a consequence, dividends of $.74 per share were paid in 1997, an
increase of approximately 8 percent from 1996. The indicated annual rate for
1998 is $.80 per share. The year 1997 was the 113th consecutive year in which
the company made dividend payments and the 30th consecutive year in which
dividends have been increased.
6
<PAGE>
<PAGE>
ENVIRONMENTAL AND LEGAL MATTERS
As with other industrial enterprises, the company's operations are subject to
complex and changing federal, state, and local environmental laws and
regulations, which will continue to require capital investment and operational
expenses. The company also has been designated a potentially responsible party
under the Comprehensive Environmental Response, Compensation and Liability Act,
commonly known as Superfund, with respect to approximately 10 sites with which
the company had varying degrees of involvement. Further, the company continues
remediation of certain of its own properties consistent with current
environmental practices. The company has accrued for estimated Superfund costs
and remediation of its own properties, taking into account, as applicable,
available information regarding site conditions, potential cleanup methods,
estimated costs and the extent to which other parties can be expected to
contribute to those costs. The company reached a settlement with its primary
liability insurance carrier providing for coverage for certain environmental
liabilities and has instituted litigation seeking coverage from certain excess
carriers. In addition, the company has accrued for certain other environmental
matters.
During 1997, the company continued to be named as a defendant in lawsuits
involving Prozac. However, continuing a trend seen in each of the past two
years, the number of pending cases declined significantly from levels of the
previous year.
The company has been named, together with numerous other U.S. prescription drug
manufacturers, as a defendant in a large number of related actions in federal
courts and the courts of several states brought by retail pharmacies and, in
some cases, consumers, alleging violations of federal and state antitrust and
pricing laws. The plaintiffs generally allege an industrywide agreement to deny
favorable prices on prescription drugs to retail pharmacies that manufacturers
grant to managed care organizations and certain other purchasers. Other suits
involve claims of price discrimination under the federal Robinson-Patman Act or
other pricing laws. In addition, claims have been brought on behalf of consumers
of prescription drugs in several states. A federal class action case involving a
majority of U.S. retail pharmacies was settled in 1995 and finalized in 1997. In
June 1997, the company settled with a number of retail pharmacy and supermarket
chains that were plaintiffs in the federal actions but had opted out of the
federal class. Those claims represented a significant portion of the remaining
federal claims. The settlement resulted in a charge in the second quarter of
1997.
Barr Laboratories, Inc. (Barr), and Geneva Pharmaceuticals, Inc. (Geneva), have
each submitted an Abbreviated New Drug Application (ANDA) seeking FDA approval
to market generic forms of Prozac before the expiration of the company's
patents. The ANDAs assert that Lilly's U.S. patents covering Prozac are invalid
and unenforceable. In April 1996, the company filed suit against Barr in federal
court in Indianapolis seeking a ruling that Barr's challenge to Lilly's patents
is without merit. In June 1997, the company filed a similar suit against Geneva
in the same court. While the company believes that the claims of Barr and Geneva
are without merit, there can be no assurance that the company will prevail. An
unfavorable outcome of this litigation could have a material adverse effect on
the company's consolidated financial position, liquidity or results of
operations.
While it is not possible to predict or determine the outcome of the patent,
product liability, antitrust or other legal actions brought against the company
or the ultimate cost of environmental matters, the company believes that, except
as noted above, the costs associated with all such matters will not have a
material adverse effect on its consolidated financial position or liquidity but
could possibly be material to the consolidated results of operations in any one
accounting period. For additional information on litigation and environmental
matters, see Note 14 to the consolidated financial statements.
7
<PAGE>
<PAGE>
PRIVATE SECURITIES LITIGATION REFORM ACT OF 1995 --
A CAUTION CONCERNING FORWARD-LOOKING STATEMENTS:
Under the safe harbor provisions of the Private Securities Litigation Reform Act
of 1995, the company cautions investors that any forward-looking statements or
projections made by the company, including those made in this document, are
based on management's expectations at the time they are made, but they are
subject to risks and uncertainties that may cause actual results to differ
materially from those projected. Economic, competitive, governmental,
technological and other factors that may affect the company's operations and
prospects are discussed in Exhibit 99 to the company's most recent report on
Forms 10-Q and 10-K filed with the Securities and Exchange Commission.
8
<PAGE>
<PAGE>
1997 Financial Highlights
ELI LILLY AND COMPANY AND SUBSIDIARIES
(Dollars in millions, except per-share data)
<TABLE>
<CAPTION>
Change
December 31 1997(1) 1996(1) (Percent)
- ---------------------------------------------------------------------------------------------
<S> <C> <C> <C>
Net sales...................................... $8,517.6 $7,346.6 16
Research and development expenses............. 1,382.0 1,189.5 16
Asset impairment.............................. 2,443.0 - -
Gain on sale of DowElanco..................... 631.8 - -
Net income (loss)............................. (385.1) 1,523.5 N/M(3)
Earnings (loss) per share..................... $ (.35) $ 1.39 N/M(3)
Earnings (loss) per share - diluted........... (.35) 1.36 N/M(3)
As adjusted(2):
Net income................................. $1,774.4 $1,454.6 22
Earnings per share......................... 1.61 1.33 21
Earnings per share - diluted............... 1.57 1.30 21
Net income as a percent of sales........... 20.8% 19.8% -
Dividends paid per share...................... $ .74 $ .685 8
Capital expenditures.......................... $ 366.3 $ 443.9 (17)
Economic Value Added (EVA'r')................... $ 751 $ 460 63
</TABLE>
(1) Per-share data for both years reflect the two-for-one stock split in
September 1997. See Note 9 to the consolidated financial statements.
(2) Reflects the results of operations excluding the impacts in 1997 of the
asset impairment, the gain on sale of DowElanco, settlement of a
significant portion of the remaining pricing litigation, a charge for
discontinuance of a research collaboration and the impact in 1996 of the
sale of U.S. marketing rights to Ceclor'r' CD and Keftab'r'. See notes to
the consolidated financial statements.
(3) Not meaningful
9
<PAGE>
<PAGE>
Consolidated Statements of Income
ELI LILLY AND COMPANY AND SUBSIDIARIES
(Dollars in millions, except per-share data)
<TABLE>
<CAPTION>
Year Ended December 31 1997 1996 1995
- ------------------------------------------------------------------------------------------
<S> <C> <C> <C>
Net sales.............................................. $8,517.6 $7,346.6 $6,763.8
Cost of sales.......................................... 2,362.9 2,118.4 1,885.7
Research and development............................... 1,382.0 1,189.5 1,042.3
Marketing and administrative........................... 2,314.4 1,991.9 1,854.0
Asset impairment (Note 2).............................. 2,443.0 - -
Gain on sale of DowElanco (Note 4)..................... (631.8) - -
Interest expense....................................... 234.1 288.8 286.3
Other income--net....................................... (97.2) (273.3) (70.1)
------- ------- -------
8,007.4 5,315.3 4,998.2
------- ------- -------
Income from continuing operations
before income taxes.................................. 510.2 2,031.3 1,765.6
Income taxes (Note 12)................................. 895.3 507.8 459.0
----- ------- -------
Income (loss) from continuing operations............... (385.1) 1,523.5 1,306.6
Discontinued operations, net of tax (Note 4)........... - - 984.3
------ ------ -----
Net income (loss)...................................... $(385.1) $1,523.5 $2,290.9
====== ======= =======
Earnings (loss) per share (Note 11):
Income (loss) from continuing operations............. $ (.35) $ 1.39 $ 1.15
Discontinued operations.............................. - - .86
------- -------- --------
Net income (loss).................................... $ (.35) $ 1.39 $ 2.01
======= ======== ========
Earnings (loss) per share - diluted (Note 11):
Income (loss) from continuing operations............. $ (.35) $ 1.36 $ 1.13
Discontinued operations.............................. - - .86
------- -------- --------
Net income (loss).................................... $ (.35) $ 1.36 $ 1.99
======= ======== ========
</TABLE>
See notes to consolidated financial statements.
10
<PAGE>
<PAGE>
Consolidated Balance Sheets
ELI LILLY AND COMPANY AND SUBSIDIARIES
(Dollars in millions)
<TABLE>
<CAPTION>
December 31 1997 1996
- -------------------------------------------------------------------------------------
<S> <C> <C>
Assets
Current Assets
Cash and cash equivalents.................................. $ 1,947.5 $ 813.7
Short-term investments..................................... 77.1 141.4
Accounts receivable, net of allowances of
$53.3 (1997) and $82.4 (1996)........................... 1,544.3 1,474.6
Other receivables.......................................... 338.9 262.5
Inventories (Note 1)....................................... 900.7 881.4
Deferred income taxes (Note 12)............................ 325.7 145.2
Prepaid expenses........................................... 186.5 172.5
------- -------
Total current assets.................................... 5,320.7 3,891.3
Other Assets
Prepaid retirement (Note 13)............................... 579.1 512.9
Investments (Note 6)....................................... 465.6 443.5
Goodwill and other intangibles, net of
allowances for amortization of $119.3 (1997)
and $311.0 (1996) (Note 2).............................. 1,550.5 4,028.2
Sundry..................................................... 559.8 1,124.3
------- -------
3,155.0 6,108.9
Property and Equipment (Note 1)............................ 4,101.7 4,307.0
------- -------
$12,577.4 $14,307.2
========= =========
</TABLE>
11
<PAGE>
<PAGE>
Consolidated Balance Sheets
ELI LILLY AND COMPANY AND SUBSIDIARIES
(Dollars in millions)
<TABLE>
<CAPTION>
December 31 1997 1996
- ----------------------------------------------------------------------------------------
<S> <C> <C> <C>
Liabilities and Shareholders' Equity
Current Liabilities
Short-term borrowings (Note 7).................................. $ 227.6 $ 1,212.9
Accounts payable............................................... 985.5 829.3
Employee compensation........................................... 456.6 388.4
Dividends payable.............................................. 221.7 198.8
Income taxes payable (Note 12)................................. 1,188.0 691.8
Other liabilities.............................................. 1,112.2 901.0
------- -------
Total current liabilities................................... 4,191.6 4,222.2
Other Liabilities
Long-term debt (Note 7)........................................ 2,326.1 2,516.5
Deferred income taxes (Note 12)................................. 215.5 376.0
Retiree medical benefit
obligation (Note 13)........................................ 118.3 136.4
Other noncurrent liabilities.................................... 920.3 956.0
------- -------
3,580.2 3,984.9
Commitments and contingencies (Note 14)........................ - -
Minority interest in subsidiary (Note 10)...................... 160.0 -
Shareholders' Equity (Notes 8 and 9)
Common stock--no par value
Authorized shares: 1,600,000,000
Issued shares: 1,111,521,927............................ 694.7 355.6
Additional paid-in capital..................................... - 67.4
Retained earnings.............................................. 4,483.1 7,207.3
Deferred costs--ESOP............................................. (155.7) (176.9)
Currency translation adjustments................................ (267.0) (57.4)
------- -------
4,755.1 7,396.0
Less cost of common stock in treasury:
1997 -- 1,000,000 shares
1996 -- 16,079,323 shares.................................. 109.5 1,295.9
----- -------
4,645.6 6,100.1
------- -------
$12,577.4 $14,307.2
========= =========
</TABLE>
See notes to consolidated financial statements.
12
<PAGE>
<PAGE>
Consolidated Statements of Cash Flows
ELI LILLY AND COMPANY AND SUBSIDIARIES
(Dollars in millions)
<TABLE>
<CAPTION>
Year Ended December 31 1997 1996 1995
- ----------------------------------------------------------------------------------------------
<S> <C> <C> <C>
Cash Flows From Operating Activities
Net income (loss)........................................ $ (385.1) $1,523.5 $2,290.9
Adjustments To Reconcile Net Income (Loss) to
Cash Flows From Operating Activities
Depreciation and amortization.......................... 509.8 543.5 553.7
Change in deferred taxes............................... (293.0) 207.3 144.0
Gain on sale of DowElanco, net of tax.................. (303.5) - -
Asset impairment, net of tax........................... 2,429.6 - -
Net gain on disposition of discontinued
operations.......................................... - - (921.5)
Other noncash income--net............................... (37.8) (97.8) (9.8)
------- ------- -------
1,920.0 2,176.5 2,057.3
Changes in operating assets and liabilities:
Receivables--(increase) decrease.................... (4.7) 104.4 (189.3)
Inventories--(increase)............................. (65.8) (42.2) (22.1)
Other assets--(increase)............................ (22.2) (51.7) (114.5)
Accounts payable and other
liabilities--increase (decrease)................. 573.1 (195.6) 93.2
------- ------ -------
480.4 (185.1) (232.7)
------- ------ -------
Net Cash From Operating Activities....................... 2,400.4 1,991.4 1,824.6
Cash Flows From Investing Activities
Acquisitions............................................. - (97.1) (36.8)
Additions to property and equipment...................... (366.3) (443.9) (551.3)
Disposals of property and equipment...................... 11.5 11.2 21.5
Additions to other assets................................ (34.2) (40.8) (54.1)
Reductions of investments................................ 365.7 396.9 430.8
Additions to investments................................. (388.5) (294.3) (372.9)
Proceeds from sale of DowElanco.......................... 1,221.5 - -
------- ------ ----
Net Cash From (Used for) Investing
Activities............................................ 809.7 (468.0) (562.8)
Cash Flows From Financing Activities
Dividends paid........................................... (818.0) (753.2) (747.2)
Purchases of common stock and other
capital transactions.................................. (351.3) (314.5) (156.0)
Issuances under stock plans.............................. 205.4 218.4 54.7
Proceeds from issuance of subsidiary stock............... 160.0 - -
Decrease in short-term borrowings........................ (1,146.0) (801.4) (967.7)
Additions to long-term debt.............................. 2.8 - 1,019.5
Reductions of long-term debt............................. (7.5) (10.4) (17.0)
-------- -------- --------
Net Cash Used for Financing Activities................... (1,954.6) (1,661.1) (813.7)
Effect of exchange rate changes on cash.................. (121.7) (48.1) 14.5
------ -------- -------
Net increase (decrease) in cash and
cash equivalents...................................... 1,133.8 (185.8) 462.6
Cash and cash equivalents at beginning
of year............................................... 813.7 999.5 536.9
----- ------- -------
Cash and cash equivalents at end of year................. $1,947.5 $ 813.7 $ 999.5
======= ======= =======
</TABLE>
See notes to consolidated financial statements.
13
<PAGE>
<PAGE>
Segment Information
<TABLE>
<CAPTION>
Industry Data (Dollars in millions) 1997 1996 1995
- -------------------------------------------------------------------------------------------
<S> <C> <C> <C>
Net sales--to unaffiliated customers
Life-sciences products and services
Central nervous system........................... $3,519.7 $2,659.4 $2,266.4
Endocrine........................................ 1,386.3 1,302.2 1,179.1
Anti-infectives.................................. 1,272.5 1,451.4 1,673.9
Animal health.................................... 589.8 547.3 512.4
Health care management........................... 548.5 372.2 259.4
Gastrointestinal................................. 526.5 531.4 548.4
Cardiovascular................................... 421.0 326.5 195.8
All other........................................ 253.3 156.2 128.4
----- ------- -------
Net sales............................................ $8,517.6 $7,346.6 $6,763.8
======= ======= =======
</TABLE>
Life-sciences products and services include a broad range of pharmaceuticals
used for the treatment of human and animal diseases and the company's
health-care-management activities. The largest category of the products is
central-nervous-system agents, which include Prozac, Zyprexa, Darvon'r' and
Permax. Endocrine products consist primarily of Humulin, Humatrope, Humalog and
Iletin'r'. Anti-infectives include Ceclor, Keflex, Lorabid, Nebcin'r',
Tazidime'r' and Vancocin. Animal health products include Tylan; Micotil;
Rumensin'r', a nonhormonal cattle feed additive; anticoccidial agents for use in
broilers and layer replacements, the largest of which is Coban'r'; and other
products for livestock and poultry. Other major groups are health care
management, of which PCS is the largest component, and gastrointestinal, all of
which is Axid. PCS derives revenue from pharmacy benefit management, such as
pharmacy claims processing and adjudication as well as physician-focused medical
communications networks. Cardiovascular products consist primarily of ReoPro and
Dobutrex. Products in the all-other category include oncology products, of which
Gemzar is the largest, and other miscellaneous pharmaceutical products.
Most of the pharmaceutical products are distributed through wholesalers that
serve physicians, dentists, pharmacies and hospitals. In 1997, the company's
four largest wholesalers each accounted for between 11 and 15 percent of
consolidated net sales. Animal health products are sold to wholesale
distributors, retailers, manufacturers and producers.
14
<PAGE>
<PAGE>
<TABLE>
<CAPTION>
Geographic Information (Dollars in millions) 1997 1996 1995
- -----------------------------------------------------------------------------------------------
<S> <C> <C> <C>
Net sales
United States
Sales to unaffiliated customers.................... $ 5,411.7 $ 4,265.6 $ 3,812.9
Transfers to other geographic areas................ 637.0 517.3 485.5
------- ------- -------
6,048.7 4,782.9 4,298.4
Europe, Middle East and Japan
Sales to unaffiliated customers.................... 2,298.1 2,310.0 2,193.8
Transfers to other geographic areas................ 1,026.0 488.3 336.9
------- ------- -------
3,324.1 2,798.3 2,530.7
Other
Sales to unaffiliated customers.................... 807.8 771.0 757.1
Transfers to other geographic areas................ 272.9 17.7 13.8
------- ------- -------
1,080.7 788.7 770.9
Eliminations - transfers between
geographic areas.................................... (1,935.9) (1,023.3) (836.2)
-------- -------- --------
$ 8,517.6 $ 7,346.6 $ 6,763.8
======== ======== ========
Income (loss) from continuing operations
before income taxes
United States...................................... $ (630.8) $ 1,273.5 $ 997.8
Europe, Middle East and Japan...................... 1,453.6 772.1 697.1
Other.............................................. 300.1 58.9 92.1
Eliminations and adjustments....................... (612.7) (73.2) (21.4)
-------- ------- -------
$ 510.2 $ 2,031.3 $ 1,765.6
======== ======= =======
Total assets
United States...................................... $12,070.7 $11,101.3 $11,321.8
Europe, Middle East and Japan...................... 2,792.3 3,332.6 3,178.0
Other.............................................. 584.2 590.7 527.0
Eliminations and adjustments....................... (2,869.8) (717.4) (614.3)
-------- -------- --------
$12,577.4 $14,307.2 $14,412.5
======== ======== ========
</TABLE>
Transfers between geographic areas are made at prices that are intended to
reasonably approximate an arms-length value of the products. Remittances to the
United States are subject to various regulations of the respective governments
as well as to fluctuations in exchange rates. The 1997 loss from continuing
operations in the United States is primarily a result of the asset impairment
(see Note 2). In addition, due primarily to the remittance of intercompany
dividends to the United States, total assets decreased in Europe, Middle East
and Japan with a corresponding increase in the United States.
15
<PAGE>
<PAGE>
Selected Quarterly Data (unaudited)
ELI LILLY AND COMPANY AND SUBSIDIARIES
(Dollars in millions, except per-share data)
<TABLE>
<CAPTION>
1997(1) Fourth Third Second First
- ---------------------------------------------------------------------------------------------------
<S> <C> <C> <C> <C>
Net sales....................... $2,415.8 $2,160.1 $1,988.7 $1,953.0
Cost of sales................... 685.0 587.8 548.8 541.3
Operating Expenses.............. 1,091.5 932.6 899.4 772.9
Asset Impairment................ - - 2,443.0 -
Gain on sale of DowElanco....... - 13.6 618.2 -
Other expense-net (29.3) (41.0) (4.6) (62.0)
Income (loss) before income
taxes........................ 610.0 612.3 (1,288.9) 576.8
Net income (loss)............... 457.5 456.9 (1,732.1) 432.6
Earning (loss) per share........ .41 .41 (1.57) .39
Earnings (loss) per share-
diluted...................... .40 .40 (1.57) .38
Dividends paid per share........ .20 .18 .18 .18
Common stock prices:
High................................. 70.44 61.75 55.75 47.50
Low.................................. 60.00 50.41 38.69 35.56
<CAPTION>
1996(1) Fourth Third(2) Second First
- -------------------------------------------------------------------------------------------------
<S> <C> <C> <C> <C>
Net sales............................... $2,061.1 $1,803.9 $1,698.3 $1,783.3
Cost of sales........................... 592.4 502.9 505.1 518.0
Operating expenses...................... 929.2 763.8 752.4 736.0
Other income (expense) - net............ (56.7) 22.2 24.5 (5.5)
Income before income taxes.............. 482.8 559.4 465.3 523.8
Net income.............................. 373.0 415.6 345.7 389.2
Earnings per share...................... .34 .38 .31 .36
Earnings per share-diluted.............. .33 .37 .31 .35
Dividends paid per share................ .1713 .1713 .1713 .1713
Common stock prices:
High................................. 40.19 33.06 33.63 33.81
Low.................................. 31.75 26.75 26.75 24.69
</TABLE>
(1) Per-share data and common stock prices for all periods reflect the
two-for-one stock split in September 1997. See Note 9 to the consolidated
financial statements.
(2) Third-quarter other income includes approximately $100 million for the sale
of the U.S. marketing rights for Ceclor CD and Keftab to Dura
Pharmaceuticals, Inc.
The company's common stock is listed on the New York, London and other stock
exchanges.
16
<PAGE>
<PAGE>
Selected Financial Data (unaudited)
ELI LILLY AND COMPANY AND SUBSIDIARIES
(Dollars in millions, except per-share data)
<TABLE>
<CAPTION>
1997 1996 1995 1994 1993
---------------------------------------------------------------
<S> <C> <C> <C> <C> <C>
Operations
Net sales......................... $8,517.6 $7,346.6 $6,763.8 $5,711.6 $5,198.5
Research and development
expenses......................... 1,382.0 1,189.5 1,042.3 838.7 755.0
Other costs and expenses.......... 4,677.3 4,110.3 3,739.7 3,136.4 2,780.4
Asset impairment.................. 2,443.0 - - - -
Gain on sale of DowElanco......... (631.8) - - - -
Restructuring and special
charges.......................... - - - 66.0 1,032.6
Income from continuing
operations before taxes
and accounting changes........... 510.2 2,031.3 1,765.6 1,698.6 662.8
Income taxes..................... 895.3 507.8 459.0 513.5 198.0
Income (loss)from:
Continuing operations
before accounting
changes........................ (385.1) 1,523.5 1,306.6 1,185.1 464.8
Discontinued operations......... - - 984.3 101.0 26.3
Net income (loss)................ (385.1) 1,523.5 2,290.9 1,286.1 480.2
Income from continuing
operations before
accounting changes as a
percent of sales................ N/M3 20.7% 19.3% 20.7% 8.9%
Per-share data - diluted(1):
Income (loss) from:
Continuing operations
before accounting
changes....................... $ (.35) $ 1.36 $ 1.13 $ 1.01 $ .39
Discontinued operations........ - - .86 .09 .02
Net income (loss)............... (.35) 1.36 1.99 1.10 .41
Dividends declared(1)............ .76 .694 .665 .63 .61
Weighted-average number of
shares-diluted(thousands)(1).... 1,101,099 1,117,110 1,152,016 1,170,916 1,177,156
========= ========= ========= ========= =========
Financial Position
Current assets.................... $5,320.7 $3,891.3 $4,138.6 $3,962.3 $3,697.1
Current liabilities............... 4,191.6 4,222.2 4,967.0 5,669.5 2,928.0
Property and equipment-net........ 4,101.7 4,307.0 4,239.3 4,411.5 4,200.2
Total assets...................... 12,577.4 14,307.2 14,412.5 14,507.4 9,623.6
Long-term debt.................... 2,326.1 2,516.5 2,592.9 2,125.8 835.2
Shareholders' equity.............. 4,645.6 6,100.1 5,432.6 5,355.6 4,568.8
======== ======= ======== ======== =======
Supplementary Data(2)
Return on shareholders'
equity........................... N/M3 26.4% 42.5% 25.9% 10.2%
Return on assets.................. N/M3 10.7% 15.6% 11.8% 5.2%
Capital expenditures.............. $ 366.3 $ 443.9 $ 551.3 $ 576.5 $ 633.5
Depreciation and
amortization..................... 509.8 543.5 553.7 432.2 398.3
Effective tax rate................ N/M3 25.0% 26.0% 30.2% 29.9%
Number of employees............... 31,100 29,200 28,500 26,400 26,200
Number of shareholders of
record........................... 58,200 54,500 52,600 55,900 59,300
======= ====== ====== ====== ======
</TABLE>
(1) Adjusted to reflect the stock splits in 1995 and 1997. See Note 9.
(2) All supplementary financial data, other than the effective tax rate, have
been computed using net income, which in 1995 includes a net gain of $921.5
million from the divestiture of discontinued operations. See Note 4. The
effective tax rate reflects continuing operations only. The number of
employees reflects continuing operations, including controlled joint
ventures.
(3) Excluding the impacts of the significant transactions reflected in 1997,
income from continuing operations before accounting changes as a percent of
sales would have been 20.8 percent and the return on shareholders' equity,
return on assets and effective tax rate would have been 33.0 percent, 13.5
percent and 25.0 percent, respectively.
17
<PAGE>
<PAGE>
Notes to Consolidated Financial Statements
ELI LILLY AND COMPANY AND SUBSIDIARIES
(Dollars in millions, except per-share data)
Note 1: Summary of Significant Accounting Policies
Basis of Presentation: The accounts of all wholly owned and majority-owned
subsidiaries are included in the consolidated financial statements. All
intercompany balances and transactions have been eliminated. The preparation of
financial statements in conformity with generally accepted accounting principles
requires management to make estimates and assumptions that affect the reported
amounts of assets, liabilities, revenues, expenses and related disclosures at
the date of the financial statements and during the reporting period. Actual
results could differ from those estimates.
The outstanding and weighted-average number of shares of common stock and
per-share data have been adjusted, for all periods presented, to reflect the
impact of the company's November 1995 and September 1997 stock splits. Treasury
shares held by the company were not split.
The company has adopted SFAS No. 128, "Earnings per Share," which requires that
both basic earnings per share and diluted earnings per share be presented on the
face of the income statement. Restatement of earnings-per-share data for
previous periods is also required. All per-share amounts, unless otherwise noted
in the footnotes, are presented on a diluted basis, that is, based on the
weighted-average number of outstanding common shares and the effect of all
potentially dilutive common shares (primarily unexercised stock options).
Cash Equivalents: The company considers all highly liquid investments, generally
with a maturity of three months or less, to be cash equivalents. The cost of
these investments approximates fair value.
Inventories: The company states all its inventories at the lower of cost or
market. The company uses the last-in, first-out (LIFO) method for substantially
all its inventories located in the continental United States, or approximately
55 percent of its total inventories. Other inventories are valued by the
first-in, first-out (FIFO) method. Inventories at December 31 consisted of the
following:
1997 1996
---- ----
Finished products............................ $262.0 $294.5
Work in process.............................. 459.4 423.4
Raw materials and supplies................... 191.0 171.7
----- -----
912.4 889.6
Less reduction to LIFO cost.................. 11.7 8.2
----- -----
$900.7 $881.4
===== =====
Investments: All short-term debt securities are classified as held-to-maturity
because the company has the positive intent and ability to hold the securities
to maturity. Held-to-maturity securities are stated at amortized cost, adjusted
for amortization of premiums and accretion of discounts to maturity.
Substantially all long-term debt and marketable equity securities are classified
as available-for-sale at December 31, 1997. Available-for-sale securities are
carried at fair value, with the unrealized gains and losses, net of tax,
reported in a separate component of shareholders' equity. The company owns no
investments that are considered to be trading securities.
Derivative Financial Instruments: The company's derivative activities, all of
which are for purposes other than trading, are initiated within the guidelines
of documented corporate risk-management policies and do not create additional
risk because gains and losses on derivative contracts offset losses and gains on
the assets, liabilities and transactions being hedged. As derivative contracts
are initiated, the company designates the instruments individually to underlying
financial instruments or anticipated transactions (i.e., underlying exposures).
Management reviews the correlation and effectiveness of its derivatives on a
periodic basis. Derivative contracts that do not qualify for deferral hedge
accounting are marked to market.
18
<PAGE>
<PAGE>
For terminations of derivatives receiving deferral accounting, gains and losses
are deferred when the related underlying exposures remain outstanding and are
included in the measurement of the related transaction or balance. In addition,
upon termination of the underlying exposures, the derivative is marked to market
and the resulting gain or loss is included with the gain or loss on the
terminated transaction. The company may redesignate the remaining derivative
instruments to other underlying exposures.
The company enters into foreign currency forward and option contracts to reduce
the effect of fluctuating currency exchange rates (principally European
currencies and the Japanese yen). Generally, foreign currency derivatives used
for hedging are put in place using the same or like currencies and duration as
the underlying exposures. Forward contracts are principally used to manage
exposures arising from affiliate foreign currency balances. These contracts are
marked to market with gains and losses recognized currently in income to offset
the respective losses and gains recognized on the underlying exposures. The
company also enters into purchased option contracts to hedge anticipated foreign
currency transactions, primarily intercompany inventory activities expected to
occur within the next year, and foreign currency forward contracts and currency
swaps to hedge firm commitments. The contracts are designated and effective as
hedges of those anticipated transactions. Gains and losses on these contracts
that qualify as hedges are deferred and recognized as an adjustment of the
subsequent transaction when it occurs. Forward and option contracts generally
have maturities not exceeding 12 months.
The company may enter into interest rate swaps to manage interest rate
exposures. The company designates the interest rate swaps as hedges of the
underlying debt. Interest expense on the debt is adjusted to include the
payments made or received under the swap agreements.
Intangible Assets: Intangible assets arising from acquisitions and research
alliances are amortized over their estimated useful lives, ranging from five to
40 years, using the straight-line method. Impairments are recognized in
operating results if impairment indicators are present and the fair value of the
related assets is less than their carrying amounts.
Property and Equipment: Property and equipment is stated on the basis of cost.
Provisions for depreciation of buildings and equipment are computed generally by
the straight-line method at rates based on their estimated useful lives. At
December 31, property and equipment consisted of the following:
1997 1996
---- ----
Land............................................. $ 130.6 $ 143.9
Buildings........................................ 2,057.1 2,103.5
Equipment........................................ 4,373.8 4,247.0
Construction in progress......................... 473.4 602.0
------- -------
7,034.9 7,096.4
Less allowances for depreciation................. 2,933.2 2,789.4
------- -------
$4,101.7 $4,307.0
======= =======
Depreciation expense related to continuing operations for 1997, 1996 and 1995
was $397.5 million, $394.9 million and $371.4 million, respectively.
Approximately $20.4 million, $35.8 million and $38.3 million of interest costs
were capitalized as part of property and equipment in 1997, 1996 and 1995,
respectively. Total rental expense for all leases related to continuing
operations, including contingent rentals (not material), amounted to
approximately $126.1 million for 1997, $119.6 million for 1996 and $106.8
million for 1995. Capital leases included in property and equipment in the
consolidated balance sheets and future minimum rental commitments are not
material. However, the company entered into capital lease obligations
aggregating $8.8 million in 1997 and $27.4 million in 1996.
Revenue Recognition: Revenue from sales of products is recognized at the time
products are shipped to the customer. Revenue from health-care-management
services is recognized when the services are delivered.
19
<PAGE>
<PAGE>
Income Taxes: Deferred taxes are recognized for the future tax effects of
temporary differences between financial and income tax reporting based on
enacted tax laws and rates. Federal income taxes are provided on the portion of
the income of foreign subsidiaries that is expected to be remitted to the United
States and be taxable.
Earnings (Loss) per Share: Earnings (loss) per share are calculated based on the
weighted-average number of outstanding common shares and incremental shares.
Diluted earnings (loss) per share are calculated based on the weighted-average
number of outstanding common shares, plus the effect of dilutive stock options
and other incremental shares.
Note 2: Asset Impairment
In November 1994, the company purchased PCS Health Systems, Inc. (PCS), McKesson
Corporation's pharmaceutical-benefits-management business, for approximately
$4.1 billion. Substantially all the purchase price was allocated to goodwill.
Subsequently, pursuant to SFAS No. 121, "Accounting for the Impairment of
Long-Lived Assets and for Long-Lived Assets to Be Disposed Of," the company
evaluated the recoverability of the long-lived assets, including intangibles, of
its PCS health-care-management businesses. While revenues and profits are
growing and new capabilities are being developed at PCS, the rapidly changing,
competitive and highly regulated environment in which PCS operates has prevented
the company from significantly increasing PCS' operating profits from levels
that existed prior to the acquisition. In addition, since the acquisition, the
health-care-industry trend toward highly managed care has been slower than
originally expected and the possibility of selling a portion of PCS' equity to a
strategic partner has not been realized. In the second quarter of 1997,
concurrent with PCS' annual planning process, the company determined that PCS'
estimated future undiscounted cash flows were below the carrying value of PCS'
long-lived assets. Accordingly, during the second quarter of 1997, the company
adjusted the carrying value of PCS' long-lived assets, primarily goodwill, to
their estimated fair value of approximately $1.5 billion, resulting in a noncash
impairment loss of approximately $2.4 billion ($2.21 per share). The estimated
fair value was based on anticipated future cash flows discounted at a rate
commensurate with the risk involved.
Note 3: Restructuring and Special Charges
In both 1993 and 1992, the company announced major actions designed to enhance
the company's competitiveness in the changing health care environment, reduce
expenses and improve efficiencies. During 1997 and 1996, the company continued
to take steps to complete these actions.
Significant components of these charges and their status at December 31, 1996
and 1997, respectively, are summarized as follows:
<TABLE>
<CAPTION>
Original
Charges 1996 1997
-------------------------------------
1993
- ----
<S> <C> <C> <C>
Work force reductions........................ $ 534.5 $ 24.7 $ -
Manufacturing consolidations
and other closings.......................... 204.3 91.8 48.1
Pharmaceutical streamlining................... 35.3 - -
Asset write-downs, legal
accruals and other.......................... 258.5 4.4 4.8
------- ----- -----
Total - continuing operations............... $1,032.6 $120.9 $ 52.9
======= ===== =====
<CAPTION>
1992
- ----
<S> <C> <C> <C>
Global manufacturing strategy................ $ 218.9 $ 59.1 $ 38.6
Legal, environmental, asbestos
abatement and other....................... 185.5 61.3 54.0
------- ----- -----
Total - continuing operations............... $ 404.4 $120.4 $ 92.6
======= ===== =====
</TABLE>
20
<PAGE>
<PAGE>
The 1993 restructuring actions consisted primarily of early-retirement and other
severance programs associated with work force reductions as well as streamlining
core pharmaceutical operations. In addition, restructuring actions in both 1993
and 1992 have resulted or will result in a consolidation of certain
manufacturing operations and changes in the nature and/or location of certain
manufacturing operations. Asset write-downs reflected changes in pharmaceutical
markets. Special charges were established for patent and product liability
matters in both 1993 and 1992.
Note 4: Divestitures
On June 30, 1997, The Dow Chemical Company acquired the company's 40 percent
interest in the DowElanco joint venture. The cash purchase price was $1.2
billion, resulting in a gain of $631.8 million ($303.5 million after-tax, or
$.28 per share).
During 1995, the company completed the divestiture of the Medical Devices and
Diagnostics (MDD) Division businesses. In 1994, a separate company, Guidant
Corporation (Guidant), was formed to be the parent company of five of the MDD
companies. In December 1994, Guidant sold approximately 20 percent of its common
stock in an initial public offering. In September 1995, the company distributed
its remaining 80 percent interest in Guidant through a splitoff. Pursuant to the
splitoff, 16,504,298 shares of the company's common stock (expressed on a
pre-stock-split basis) were exchanged by company shareholders for the Guidant
stock. The splitoff resulted in a tax-free gain calculated as the difference
between the market and carrying values of the shares of Guidant common stock
held by the company on the expiration date of the exchange offer. Sales of the
other MDD companies were all finalized by January 1996.
The income from discontinued operations appearing on the consolidated statements
of income represents the results of the MDD division for the periods presented
and the net gain upon divestiture and is summarized as follows:
1995
----
Net sales............................................................ $ 771.6
Cost of sales........................................................ 258.2
Other operating expenses............................................. 356.8
Income before tax.................................................... 111.9
Income from operations, net of tax................................... 62.8
Net gain on disposition, net of tax ($88.1 million).................. 921.5
-----
Discontinued operations.............................................. $ 984.3
=====
Note 5: Implementation of New Financial Accounting Standards
In June 1997, SFAS No. 130, "Reporting Comprehensive Income," was issued. The
statement must be adopted by the company in the first quarter of 1998. Under
provisions of this statement, the company will be required to include a
financial statement presentation of comprehensive income and its components to
conform to these new requirements. As a consequence of this change, certain
reclassifications will be necessary for previously reported amounts to achieve
the required presentation of comprehensive income. Implementation of this
disclosure standard will not affect the company's financial position or results
of operations.
In June 1997, SFAS No. 131, "Disclosure about Segments of an Enterprise and
Related Information," was issued. The statement must be adopted by the company
on December 31, 1998. Under provisions of this statement, the company will be
required to modify or expand the financial statement disclosures for operating
segments, products and services, and geographic areas. Implementation of this
disclosure standard will not affect the company's financial position or results
of operations.
In December 1997, SFAS No. 132, "Employers' Disclosures about Pensions and Other
Postretirement Benefits," was issued and is effective for the company's
21
<PAGE>
<PAGE>
1998 fiscal year. The statement revises current disclosure requirements for
employers' pensions and other retiree benefits. Implementation of this
disclosure standard will not affect the company's financial position or results
of operations.
Note 6: Financial Instruments
Risk-Management Instruments and Off-Balance-Sheet Risk
In the normal course of business, operations of the company are exposed to
fluctuations in currency values and interest rates. These fluctuations can vary
the costs of financing, investing and operating. The company addresses a portion
of these risks through a controlled program of risk management that includes the
use of derivative financial instruments.
The notional amounts of derivatives summarized in the following paragraphs do
not represent amounts exchanged by the parties and thus are not a measure of the
exposure of the company through its use of derivatives. The company is exposed
to credit-related losses in the event of nonperformance by counterparties to
financial instruments, but it does not expect any counterparties to fail to meet
their obligations given their high credit ratings.
At December 31, the stated, or notional, amounts of the company's outstanding
derivative financial instruments were as follows:
<TABLE>
<CAPTION>
1997 1996
---- ----
<S> <C> <C>
Forward exchange contracts.................................. $ 593.9 $ 688.2
Foreign currency options - purchased........................ 504.5 331.9
Interest rate swaps......................................... 30.0 30.0
</TABLE>
Financial instruments that potentially subject the company to credit risk
consist principally of trade receivables and interest-bearing investments.
Wholesale distributors of life-sciences products and managed care organizations
account for a substantial portion of trade receivables; collateral is generally
not required. The risk associated with this concentration is limited due to the
company's ongoing credit review procedures. The company places substantially all
its interest-bearing investments with major financial institutions, in U.S.
Government securities or with top-rated corporate issuers. In accordance with
documented corporate policies, the company limits the amount of credit exposure
to any one financial institution.
Fair Value of Financial Instruments
A summary of the company's outstanding financial instruments at December 31
follows. As summarized, "cost" relates to investments while "carrying amount"
relates to long-term debt.
<TABLE>
<CAPTION>
1997 1996
-------------------------------------------------
Cost/Carrying Fair Cost/Carrying Fair
Amount Value Amount Value
------ ----- ------ -----
<S> <C> <C> <C> <C>
Short-term investments:
Debt securities........... $ 77.1 $ 76.9 $ 141.4 $ 144.5
Noncurrent investments:
Marketable equity......... 77.7 86.0 72.0 91.4
Debt securities........... 93.0 93.3 56.9 57.0
Nonmarketable equity...... 34.2 33.7 20.3 19.0
Long-term debt...................... 2,266.4 2,426.5 2,465.5 2,511.6
</TABLE>
The company determines fair values based on quoted market values where available
or discounted cash flow analyses (principally long-term debt). The fair values
of nonmarketable equity securities, which represent either equity investments in
start-up technology companies or partnerships that invest in start-up technology
companies, are estimated based on the fair value
22
<PAGE>
<PAGE>
information provided by these ventures. The fair value and carrying amount of
risk-management instruments were not material at December 31, 1997 or 1996.
At December 31, 1997 and 1996, the gross unrealized holding gains on
available-for-sale securities were $19.1 million and $27.5 million,
respectively, and the gross unrealized holding losses were $13.8 million and
$9.4 million, respectively. Substantially all these gains and losses are
associated with the marketable equity securities. The proceeds from sales of
available-for-sale securities totaled $39.7 million and $102.1 million in 1997
and 1996, respectively. Realized gains and losses were $6.6 million and $25.3
million, respectively, in 1997. Purchases of available-for-sale securities were
not significant in 1997 and 1996. The net adjustment to unrealized gains and
losses on available-for-sale securities reduced shareholders' equity by $7.7
million and $39.0 million in 1997 and 1996, respectively.
The company is a limited partner in certain affordable housing investments that
generate benefits in the form of tax credits. The determination of fair value of
these investments is not practicable. The carrying value of such investments was
$253.2 million and $276.3 million as of December 31, 1997 and 1996,
respectively.
Note 7: Borrowings
Long-term debt at December 31 consisted of the following:
<TABLE>
<CAPTION>
1997 1996
---------------------------
<S> <C> <C>
6.57 to 7.13 percent notes (due 2016-2036)................... $1,000.0 $1,000.0
6.25 to 8.38 percent notes (due 1999-2006)................... 750.0 750.0
5.50 to 8.38 percent Eurodollar bonds
(due 1998-2005)........................................... 500.0 500.0
7.10 percent medium-term notes (due 1999) 36.5 100.7
8.18 percent ESOP debentures (due 2006)...................... 100.6 114.4
Other, including capitalized leases.......................... 137.3 178.6
------- -------
2,524.4 2,643.7
Less current portion......................................... 198.3 127.2
------- -------
$2,326.1 $2,516.5
======== =======
</TABLE>
The 8.18 percent Employee Stock Ownership Plan (ESOP) debentures are obligations
of the ESOP but are shown on the consolidated balance sheet because they are
guaranteed by the company. The principal and interest on the debt will be funded
by contributions from the company and by dividends received on certain shares
held by the ESOP. Because of the amortizing feature of the ESOP debt,
bondholders will receive both interest and principal payments each quarter.
The aggregate amounts of maturities on long-term debt for the next five years
are as follows: 1998, $198.3 million; 1999, $167.9 million; 2000, $221.3
million; 2001, $168.6 million; and 2002, $17.7 million.
At December 31, 1997, short-term borrowings included $29.3 million of notes
payable to banks. At December 31, 1996, commercial paper and notes payable to
banks totaled $1 billion and $85.7 million, respectively, with a
weighted-average interest rate of 5.7 percent. At December 31, 1997, unused
committed lines of credit totaled $2 billion. Compensating balances and
commitment fees are not material, and there are no conditions that are probable
of occurring under which the lines may be withdrawn.
Cash payments of interest on borrowings totaled $243.9 million, $292.9 million
and $271.7 million in 1997, 1996 and 1995, respectively.
Note 8: Stock Plans
Stock options and performance awards have been granted to officers and other
executive and key employees. Stock options are granted at exercise prices equal
to the fair market value of the company's stock at the dates of grant.
Generally, options vest 100 percent three years from the grant date and have a
term of 10 years.
23
<PAGE>
<PAGE>
In October 1995, the company issued its second grant under the GlobalShares
program. Essentially all employees were given an option to buy 400 shares of the
company's common stock at a price equal to the fair market value of the
company's stock at the date of grant. Options to purchase approximately 10.3
million shares were granted as part of the program. Individual grants generally
become exercisable on or after the third anniversary of the grant date and have
a term of 10 years.
The company has elected to follow Accounting Principles Board Opinion (APB) No.
25, "Accounting for Stock Issued to Employees" and related interpretations in
accounting for its stock options. Under APB No. 25, because the exercise price
of the company's employee stock options equals the market price of the
underlying stock on the date of grant, no compensation expense is recognized.
Total compensation expense for stock-based awards reflected in income on a
pretax basis was $242.1 million, $164.2 million, and $93.1 million in 1997, 1996
and 1995, respectively. However, SFAS No. 123, "Accounting for Stock-Based
Compensation," requires presentation of pro forma information as if the company
had accounted for its employee stock options granted subsequent to December 31,
1994, under the fair value method of that statement. For purposes of pro forma
disclosure, the estimated fair value of the options is amortized to expense over
the vesting period. Under the fair value method, the company's net income (loss)
and earnings (loss) per share would have been as follows:
<TABLE>
<CAPTION>
1997 1996 1995
---- ---- ----
<S> <C> <C> <C>
Net income (loss)....................................... $(424.2) $1,496.5 $2,285.3
Earnings (loss) per share - diluted.................... $(0.39) $1.34 $1.98
</TABLE>
Because SFAS No. 123 is applicable only to options granted subsequent to
December 31, 1994, and the options have a three-year vesting period, the pro
forma effect will not be fully reflected until 1998.
The weighted-average fair value of the individual options granted during 1997,
1996, and 1995 is estimated as $15.55, $8.25 and $5.03, respectively, on the
date of grant. The fair values for both years were determined using a
Black-Scholes option-pricing model with the following assumptions:
<TABLE>
<CAPTION>
1997 1996 1995
---- ---- ----
<S> <C> <C> <C>
Dividend yield............................ 3.14% 3.24% 3.28%
Volatility................................ 21.5% 21.0% 19.7%
Risk-free interest rate................... 6.18% 6.36% 5.87%
Forfeiture rate........................... 0 0 0
Expected life............................. 7 years 7 years 7 years
</TABLE>
Stock option activity during 1995-1997 is summarized below:
<TABLE>
<CAPTION>
Shares of Weighted-Average
Common Stock Exercise
Attributable Price of
to Options Options
-------------------------------------------
<S> <C> <C> <C>
Unexercised at January 1, 1995............ 62,162,720 $13.43
Granted................................... 21,541,326 23.25
Exercised................................. (5,784,356) 10.60
Forfeited................................. (2,686,100) 12.12
-----------
Unexercised at December 31, 1995.......... 75,233,590 16.51
Granted................................... 6,340,874 33.55
Exercised................................. (14,583,420) 12.94
Forfeited................................. (1,081,168) 20.93
-----------
Unexercised at December 31, 1996.......... 65,909,876 18.86
Granted................................... 5,854,408 64.73
Exercised................................. (10,072,728) 13.88
Forfeited................................. (797,912) 22.30
-----------
Unexercised at December 31, 1997.......... 60,893,644 24.05
===========
</TABLE>
24
<PAGE>
<PAGE>
The following table summarizes information concerning outstanding and
exercisable options at December 31, 1997 (shares in millions, contractual life
in years):
<TABLE>
<CAPTION>
Options Outstanding Options Exercisable
- --------------- ------------------------------------------- ----------------------------
Weighted-
Average Weighted- Weighted-
Range of Remaining Average Average
Exercise Number Contractual Exercise Number Exercise
Prices Outstanding Life Price Exercisable Price
- --------------- ------------------------------------------- ----------------------------
<S> <C> <C> <C> <C> <C>
$ 5 - $15 20.9 5.5 $12.78 20.9 $12.78
$15 - $20 6.0 3.8 $17.04 5.6 $16.99
$20 - $30 22.2 7.2 $23.05 2.7 $20.47
$30 - $65 11.8 9.3 $49.33 .4 $32.14
</TABLE>
Shares exercisable at December 31, 1997 were 29,559,024 (1996 - 30,565,500
shares, 1995 - 26,792,490 shares).
At December 31, 1997, additional options, performance awards or restricted stock
grants may be granted under the 1994 Lilly Stock Plan for not more than
1,312,218 shares (1996 - 6,586,656 shares, 1995 - 14,732,006 shares).
25
<PAGE>
<PAGE>
Note 9: Shareholders' Equity
Changes in the components of shareholders' equity were as follows:
<TABLE>
<CAPTION>
Common Stock in
Additional Deferred Treasury
Paid-in Retained Costs-- ---------------
Capital Earnings ESOP Shares Amount
--------- -------- ------- ---------------
<S> <C> <C> <C> <C> <C> <C>
Balance at January 1, 1995.......... $ 421.7 $5,062.1 $(218.2) 871,514 $ 55.0
Net income.......................... 2,290.9
Cash dividends declared per
share: $.665..................... (747.8)
Stock dividend declared............. (172.6)
Purchase for treasury............... 2,630,000 160.0
Increase in treasury shares
from Guidant exchange
transaction (Note 4).............. 10.9 16,504,298 1,533.6
Issuance of stock under
employee stock plans............. (24.1) (1,841,175) (122.0)
ESOP transactions................... 9.9 18.7
Unrealized investment gains
and losses, net of tax........... 52.9
Other............................... (0.1) (1.2) (15,143) (1.1)
----- ------- ------ ---------- -------
Balance at December 31, 1995 418.3 6,484.3 (199.5) 18,149,494 1,625.5
Net income.......................... 1,523.5
Cash dividends declared per
share: $.695...................... (762.9)
Purchase for treasury............... 5,315,000 318.5
Issuance of stock under
employee stock plans.............. (368.4) (7,384,672) (648.0)
ESOP transactions................... 17.5 22.6
Unrealized investment gains
and losses, net of tax........... (39.0)
Other................................ 1.4 (499) (0.1)
------- ------- ------- ---------- -------
Balance at December 31, 1996........ 67.4 7,207.3 (176.9) 16,079,323 1,295.9
Net loss............................ (385.1)
Cash dividends declared
per share: $0.76................. (840.9)
Stock dividend declared............. (346.5)
Retirement of treasury shares....... (1,134.5) (14,223,272) (1,143.4)
Purchase for treasury............... 3,400,000 355.3
Issuance of stock under
employee stock plans............. (99.7) (4,247,216) (397.4)
ESOP transactions................... 39.6 21.2
Unrealized investment gains
and losses, net of tax........... (7.7)
Other............................... (0.3) (16.5) (8,835) (0.9)
Reclassification.................... 1,127.5 (1,127.5)
------- -------
Balance at December 31,1997......... $ 0.0 $4,483.1 $(155.7) 1,000,000 $ 109.5
======== ======= ====== ========= =======
</TABLE>
On September 15, 1997, the company's board of directors declared a two-for-one
stock split to be effected in the form of a 100 percent stock dividend payable
to shareholders of record at the close of business September 24, 1997. The
outstanding and weighted-average number of shares of common stock and per-share
data in these financial statements have been adjusted to reflect the impact of
the stock split for all periods presented. The company now has 1,111,521,927
issued shares of common stock without par value, including 554,331,485 shares
issued October 15, 1997, as a result of the stock split. Treasury shares held by
the company were not split.
The company has an Employee Stock Ownership Plan (ESOP) as a funding vehicle for
the existing employee savings plan. The ESOP used the proceeds of a loan from
the company to purchase shares of common stock from the treasury. In 1991, the
ESOP issued $200 million of third-party debt, repayment of which was guaranteed
by the company (see Note 7). The proceeds were used to purchase shares of the
company's common stock on the open market. Shares of common stock held by the
ESOP will be allocated to participating employees annually through 2006 as part
of the company's savings plan contribution. The fair value of shares allocated
each period is recognized as compensation expense.
26
<PAGE>
<PAGE>
Generally, the assets and liabilities of foreign operations are translated into
U.S. dollars using the current exchange rate. For those operations, changes in
exchange rates generally do not affect cash flows; therefore, resulting
translation adjustments are made to shareholders' equity rather than to income.
Under the terms of the company's Shareholder Rights Plan, all shareholders of
common stock received for each share owned a preferred stock purchase right
entitling them to purchase from the company one four-hundredth of a share of
Series A Participating Preferred Stock at an exercise price of $40.625. The
rights are not exercisable until after the date on which the company's right to
redeem has expired. The company may redeem the rights for $.00125 per right up
to and including the tenth business day after the date of a public announcement
that a person (the "Acquiring Person") has acquired ownership of stock having 20
percent or more of the company's general voting power (the "Stock Acquisition
Date").
The plan provides that, if the company is acquired in a business combination
transaction at any time after a Stock Acquisition Date, generally each holder of
a right will be entitled to purchase at the exercise price a number of the
acquiring company's shares having a market value of twice the exercise price.
The plan also provides that, in the event of certain other business
combinations, certain self-dealing transactions or the acquisition by a person
of stock having 25 percent or more of the company's general voting power,
generally each holder of a right will be entitled to purchase at the exercise
price a number of shares of the company's common stock having a market value of
twice the exercise price. Any rights beneficially owned by an Acquiring Person
shall not be entitled to the benefit of the adjustments with respect to the
number of shares described above. The rights will expire on July 28, 1998,
unless redeemed earlier by the company.
Note 10: Minority Interest in Subsidiary
In October of 1997, a domestic subsidiary of the company issued $160 million
(160 shares) of convertible Class B stock to an institutional investor. The
Class B stock pays dividends on a quarterly basis at 25 basis points above the
three-month LIBOR rate. The Class B stock is convertible on a one-to-one basis
into the subsidiary's Class A stock at the option of the holder at any time. The
subsidiary may redeem the Class B stock for $1 million per share plus accrued
and unpaid dividends five years from the date of issuance and upon each
fifth-year anniversary thereafter. Also, the stock may be redeemed by the
subsidiary upon various redemption events, as defined in the stockholder's
agreement, or at the option of the holder seven years from the date of issuance
for $1 million per share plus accrued and unpaid dividends.
27
<PAGE>
<PAGE>
Note 11: Earnings (Loss) Per Share
The following is a reconciliation of the numerators and denominators used in
computing earnings (loss) per share from continuing operations:
<TABLE>
<CAPTION>
1997 1996 1995
------------------------------------------
(Shares in thousands)
<S> <C> <C> <C>
Income (Loss) Available to Common
Shareholders:
Income (loss) from continuing
operations............................. $(385.1) $1,523.5 $1,306.6
Preferred stock dividend................. (2.6) (3.6) -
------ ------- -----
Income (loss) available to common
shareholders.......................... $(387.7) $1,519.9 $1,306.6
====== ======= =======
Earnings (Loss) per Share:
Weighted-average number of common
shares outstanding, including
incremental shares..................... 1,101,099 1,093,920 1,138,376
--------- --------- ---------
Earnings (loss) per share from
continuing operations.................. $ (0.35) $ 1.39 $ 1.15
========= ========= =========
Diluted Earnings (Loss) per Share:
Weighted-average number of common
shares outstanding.................... 1,101,099 1,093,654 1,138,052
Stock options and other incremental
shares................................ - 23,456 13,964
--------- --------- ---------
Weighted-average number of common
shares outstanding - diluted.......... 1,101,099 1,117,110 1,152,016
--------- --------- ---------
Diluted earnings (loss) per share
from continuing operations............ $ (0.35) $ 1.36 $ 1.13
========= ========= =========
</TABLE>
For 1997, because the inclusion of stock options and other incremental shares
would be antidilutive, earnings per share has been calculated assuming no
incremental shares. For diluted earnings (loss) per share, stock options and
other incremental shares aggregated 29,480,000 for 1997.
Note 12: Income Taxes
Following is the composition of income taxes attributable to continuing
operations:
<TABLE>
<CAPTION>
1997 1996 1995
---- ---- ----
<S> <C> <C> <C>
Current:
Federal....................................... $765.7 $306.0 $177.0
Foreign....................................... 392.3 143.1 140.1
State......................................... 52.3 7.4 3.8
------- ----- -----
1,210.3 456.5 320.9
Deferred:
Federal....................................... (281.2) 26.6 114.2
Foreign....................................... 9.6 7.8 1.9
State......................................... (43.4) 16.9 22.0
------ ------ -----
(315.0) 51.3 138.1
------ ------ -----
Income taxes..................................... $ 895.3 $ 507.8 $459.0
====== ====== =====
</TABLE>
28
<PAGE>
<PAGE>
Significant components of the company's deferred tax assets and liabilities as
of December 31 are as follows:
<TABLE>
<CAPTION>
1997 1996
---- ----
<S> <C> <C>
Deferred tax assets:
Foreign tax credit and other
carryforwards................................... $ 451.7 $ 68.0
Inventory................................. 248.7 73.6
Compensation and benefits................. 173.1 149.9
Litigation, environmental and asbestos.... 77.2 91.4
Restructuring and special charges......... 40.3 91.0
Other..................................... 263.4 266.5
------- -----
1,254.4 740.4
Valuation allowances...................... (110.2) (63.0)
------ -----
Total deferred tax assets.............. 1,144.2 677.4
Deferred tax liabilities:
Property and equipment.................... (555.9) (570.0)
Prepaid employee benefits................. (229.6) (215.7)
Other..................................... (213.3) (61.4)
------ ------
Total deferred tax liabilities......... (998.8) (847.1)
------ ------
Deferred tax assets (liabilities)--net.................. $ 145.4 $ (169.7)
======= =======
</TABLE>
At December 31, 1997, the company had carryforwards for income tax purposes of
$409.7 million: $290.9 million will expire within five years and $68 million
thereafter; $50.8 million of the carryforwards will never expire.
Unremitted earnings of foreign subsidiaries that have been, or are intended to
be, permanently reinvested for continued use in foreign operations and which, if
distributed, would result in taxes at approximately the U.S. statutory rate,
aggregated $115 million at December 31, 1997 ($1,883 million at December 31,
1996). However, the company expects to remit certain earnings in the future on
which $152.0 million in deferred tax liabilities have been accrued. Cash
payments of taxes totaled $542 million, $289 million and $449 million in 1997,
1996 and 1995, respectively.
Following is a reconciliation of the effective income tax of the continuing
operations:
<TABLE>
<CAPTION>
1997 1996 1995
------------------------------------
<S> <C> <C> <C>
United States federal statutory tax.................... $178.6 $711.0 $618.0
Add (deduct):
Asset impairment...................................... 841.6 - -
General business credits.............................. (64.3) (35.0) (21.5)
Sale of investments................................... (48.4) - -
International operations including
Puerto Rico......................................... (37.2) (189.1) (174.8)
Nondeductible goodwill amortization................... 25.9 40.3 36.8
Sundry................................................ (0.9) (19.4) 0.5
----- ----- -----
Effective income tax................................... $895.3 $507.8 $459.0
===== ===== =====
</TABLE>
Excluding the impact of the asset impairment and gain on the sale of DowElanco,
the effective income tax rate for 1997 would be 25 percent compared with 25
percent in 1996 and 26 percent in 1995.
Note 13: Retirement Benefits
Pension Plans:
The company has noncontributory defined benefit retirement plans that cover
substantially all United States employees and a majority of employees in other
countries. Benefits under the domestic plans are calculated by using one of
several formulas. These formulas are based on a combination of the following:
(1) years of service, (2) final average earnings, (3) primary social security
29
<PAGE>
<PAGE>
benefit and (4) age. The benefits for the company's plans in countries other
than the United States are based on years of service and compensation.
The company's funding practice for all plans is consistent with local
governmental and tax funding regulations. Generally, pension costs accrued are
funded. Plan assets consist primarily of equity and fixed income instruments.
Net pension expense for the company's retirement plans included the following
components related to continuing operations:
<TABLE>
<CAPTION>
1997 1996 1995
---- ---- ----
<S> <C> <C> <C>
Service cost--benefits earned during the
year............................................. $ 89.2 $ 84.4 $ 69.8
Interest cost on projected benefit
obligations...................................... 179.0 167.2 160.2
Actual return on assets............................. (407.7) (356.1) (434.8)
Net amortization and deferral....................... 164.0 130.2 227.4
------- ------- -------
Net annual pension expense.......................... $ 24.5 $ 25.7 $ 22.6
======= ======= =======
</TABLE>
The funded status and amounts recognized in the consolidated balance sheets for
the company's defined benefit retirement plans at December 31 were as follows:
<TABLE>
<CAPTION>
Assets Exceed Accumulated Benefits
Accumulated Benefits Exceed Assets
1997 1996 1997 1996
--------------------------------------------------------
<S> <C> <C> <C> <C>
Plan assets at fair
value............................. $2,923.2 $2,629.2 $ - $ -
Actuarial present value
of benefit obligations:
Vested benefits................. 1,858.9 1,721.5 126.2 113.3
Nonvested benefits.............. 126.8 112.7 5.4 2.5
------- ------- ------ -----
Accumulated benefit
obligation........................ 1,985.7 1,834.2 131.6 115.8
Effect of projected future
salary increases.................. 420.7 348.2 12.9 5.3
------- ------- ------ -----
Projected benefit
obligation........................ 2,406.4 2,182.4 144.5 121.1
------- ------- ------- -----
Funded status....................... 516.8 446.8 (144.5) (121.1)
Unrecognized net
(gain) loss....................... (44.5) (43.1) 30.7 6.3
Unrecognized prior
service cost...................... 104.9 107.5 13.1 14.8
Unrecognized net
obligation at
January 1, 1986................... 1.9 1.7 1.1 1.4
Additional minimum
liability......................... - - (32.0) (17.2)
------- ------- ------ ------
Prepaid (accrued)
pension cost...................... $ 579.1 $ 512.9 $(131.6) $(115.8)
======= ======= ====== ======
</TABLE>
The assumptions used to develop net periodic pension expense from continuing
operations and the actuarial present value of projected benefit obligations are
shown below:
<TABLE>
<CAPTION>
(percents) 1997 1996 1995
-----------------------------
<S> <C> <C> <C>
Weighted-average discount rate....................... 7.5 8.1 7.6
Rate of increase in future
compensation levels............................... 4.0-8.0 4.5-8.0 4.5-9.5
Weighted-average expected long-term
rate of return on plan assets..................... 10.5 10.5 10.5
</TABLE>
The discount rate decrease at December 31, 1997, increased the projected benefit
obligation by approximately $177.2 million.
30
<PAGE>
<PAGE>
The company has defined contribution savings plans that cover its eligible
employees worldwide. The purpose of these defined contribution plans is
generally to provide additional financial security during retirement by
providing employees with an incentive to make regular savings. Company
contributions to the plans are based on employee contributions and the level of
company match. Expenses attributable to continuing operations under the plans
totaled $46.8 million, $42.6 million and $38.3 million for the years 1997, 1996
and 1995, respectively.
Retiree Health Benefits:
The company's noncontributory defined benefit postretirement plans provide
health benefits for the majority of the United States retirees and their
eligible dependents. Certain of the company's non-U.S. subsidiaries have similar
plans for retirees. Eligibility for these benefits is based upon retirement from
the company. An eligible employee's credited service period begins when the
combination of an employee's age and years of service equals 60.
The company's funding practice for all plans is consistent with local
governmental and tax funding regulations. Plan assets consist primarily of
equity and fixed income instruments.
Net postretirement benefit expense from continuing operations included the
following components:
<TABLE>
<CAPTION>
1997 1996 1995
---- ---- ----
<S> <C> <C> <C>
Service cost--benefits earned during
the year ....................................... $ 11.2 $ 11.7 $ 9.8
Interest cost on accumulated
postretirement benefit obligations............... 31.6 28.8 24.7
Actual return on assets............................ (30.1) (29.7) (20.4)
Net amortization and deferral...................... 5.2 6.0 (4.9)
----- ----- -----
Net periodic postretirement benefit cost........... $ 17.9 $ 16.8 $ 9.2
===== ===== =====
</TABLE>
The funded status and amounts recognized in the consolidated balance sheets for
the company's defined benefit postretirement plans at December 31 were as
follows:
1997 1996
---- ----
Accumulated postretirement benefit obligation:
Retirees.................................. $ 339.3 $308.4
Fully eligible active plan participants... 66.7 35.9
Other active plan participants............ 71.5 67.8
------ -----
477.5 412.1
Plan assets at fair value.................... 228.1 200.1
------ -----
Accumulated postretirement benefit obligation
in excess of plan assets.................. 249.4 212.0
Unrecognized benefit of plan amendment....... 3.1 11.0
Unrecognized net loss........................ (134.2) (86.6)
------ -----
Accrued postretirement benefit cost.......... $ 118.3 $136.4
====== =====
The assumptions used to develop the net postretirement benefit expense from
continuing operations and the present value of the accumulated postretirement
benefit obligations are shown below:
<TABLE>
<CAPTION>
(percents) 1997 1996 1995
---- ---- ----
<S> <C> <C> <C>
Weighted-average discount rate............... 7.5 8.0 7.5
Expected long-term rate of return...................... 10.5 10.5 10.5
Health care cost trend rate for
participants:
Under age 65........................... 7.0 7.0 7.0
Over age 65............................ 5.0 5.0 5.0
</TABLE>
If these trend rates were to be increased by one percentage point each future
year, the December 31, 1997, accumulated postretirement benefit obligation would
increase by 10 percent and the aggregate of the service and interest cost
components of 1997 annual expense from continuing operations would increase by
14 percent. The decrease in the discount rate at December 31,
31
<PAGE>
<PAGE>
1997, increased the accumulated postretirement benefit obligation by
approximately $27.5 million.
Postemployment Benefits:
The company provides certain other postemployment benefits, primarily related to
disability benefits, and accrues for the related cost over the service lives of
the employees. Expenses associated with these benefit plans in 1997, 1996 and
1995 were not significant.
Note 14: Contingencies
The company has been named as a defendant in numerous product liability lawsuits
involving primarily two products, diethylstilbestrol and Prozac. The company has
accrued for its estimated exposure, including costs of litigation, with respect
to all current product liability claims. In addition, the company has accrued
for certain future anticipated product liability claims to the extent the
company can formulate a reasonable estimate of their costs. The company's
estimates of these expenses are based primarily on historical claims experience
and data regarding product usage. The company expects the cash amounts related
to the accruals to be paid out over the next several years. The majority of
costs associated with defending and disposing of these suits are covered by
insurance. The company's estimate of insurance recoverables is based on existing
deductibles, coverage limits, and the existing and projected future level of
insolvencies among its insurance carriers.
Under the Comprehensive Environmental Response, Compensation, and Liability Act,
commonly known as Superfund, the company has been designated as one of several
potentially responsible parties with respect to certain sites. Under Superfund,
each responsible party may be jointly and severally liable for the entire amount
of the cleanup. The company also continues remediation of certain of its own
sites. The company has accrued for estimated Superfund cleanup costs,
remediation and certain other environmental matters, taking into account, as
applicable, available information regarding site conditions, potential cleanup
methods, estimated costs and the extent to which other parties can be expected
to contribute to payment of those costs. The company has reached a settlement
with its primary liability insurance carrier providing for coverage for certain
environmental liabilities and has instituted litigation seeking coverage from
certain excess carriers.
The company has been named, along with numerous other U.S. prescription drug
manufacturers, as a defendant in a large number of related actions brought by
retail pharmacies alleging violations of federal and state antitrust and pricing
laws. The federal suits include a class action on behalf of the majority of U.S.
retail pharmacies. The company and several other manufacturers have settled the
federal class action case and the anticipated settlement was accrued in the
fourth quarter of 1995. That settlement is now final. Separately, in June 1997
the company reached a settlement with a large number of the remaining plaintiffs
in the federal case. Still pending are related suits brought in federal and
several state courts by a large number of retail pharmacies involving claims of
price discrimination or claims under other pricing laws. Additional cases have
been brought on behalf of consumers in several states.
The environmental liabilities and litigation accruals have been reflected in the
company's consolidated balance sheet at the gross amount of approximately $365
million. Estimated insurance recoverables of approximately $240 million have
been reflected as assets in the consolidated balance sheet.
Barr Laboratories, Inc. (Barr), and Geneva Pharmaceuticals, Inc. (Geneva), have
each submitted an Abbreviated New Drug Application (ANDA) seeking FDA approval
to market generic forms of Prozac before the expiration of the company's
patents. The ANDAs assert that Lilly's U.S. patents covering Prozac are invalid
and unenforceable. In April 1996, the company filed suit against Barr in federal
court in Indianapolis seeking a ruling that Barr's challenge to Lilly's patents
is without merit. In June 1997, the company filed a similar suit against Geneva
in the same court. While the company believes
32
<PAGE>
<PAGE>
that the claims of Barr and Geneva are without merit, there can be no assurance
that the company will prevail. An unfavorable outcome of this litigation could
have a material adverse effect on the company's consolidated financial position,
liquidity or results of operations.
While it is not possible to predict or determine the outcome of the product
liability, antitrust, patent or other legal actions brought against the company
or the ultimate cost of environmental matters, the company believes that, except
as noted above, the costs associated with all such matters will not have a
material adverse effect on its consolidated financial position or liquidity but
could possibly be material to the consolidated results of operations in any one
accounting period.
33
<PAGE>
<PAGE>
Responsibility for Financial Statements
Eli Lilly and Company and Subsidiaries
The consolidated financial statements and related notes have been prepared by
management, who are responsible for their integrity and objectivity. The
statements have been prepared in accordance with generally accepted accounting
principles and include amounts based on judgments and estimates by management.
The other financial information in this annual report is consistent with that in
the financial statements.
The company maintains internal accounting control systems that are designed to
provide reasonable assurance that assets are safeguarded, that transactions are
executed in accordance with management's authorization and are properly
recorded, and that accounting records are adequate for preparation of financial
statements and other financial information. The design, monitoring and revision
of internal accounting control systems involve, among other things, management's
judgments with respect to the relative cost and expected benefits of specific
control measures. A staff of internal auditors regularly monitors, on a
worldwide basis, the adequacy and effectiveness of internal accounting controls.
In addition to the system of internal accounting controls, the company maintains
guidelines of company policy emphasizing proper overall business conduct,
possible conflicts of interest, compliance with laws and confidentiality of
proprietary information. The guidelines are reviewed on a periodic basis with
employees worldwide.
The financial statements have been audited by Ernst & Young LLP, independent
auditors. Their responsibility is to examine the company's financial statements
in accordance with generally accepted auditing standards and to express their
opinion with respect to the fairness of presentation of the statements.
The members of the audit committee of the board of directors, none of whom are
employees of the company, recommend independent auditors for appointment by the
board of directors, review the services performed by the independent auditors,
and receive and review the reports submitted by them. The audit committee meets
several times during the year with management, the internal auditors and the
independent auditors to discuss audit activities, internal controls and
financial reporting matters. The internal auditors and the independent auditors
have full and free access to the committee.
Randall L. Tobias Charles E. Golden
Chairman of the Board and Executive Vice President and Chief
Chief Executive Officer Financial Officer
January 30, 1998
34
<PAGE>
<PAGE>
Report of Independent Auditors
Board of Directors and Shareholders
Eli Lilly and Company
We have audited the accompanying consolidated balance sheets of Eli Lilly and
Company and subsidiaries as of December 31, 1997 and 1996, and the related
consolidated statements of income and cash flows for each of the three years in
the period ended December 31, 1997. These financial statements are the
responsibility of the company's management. Our responsibility is to express an
opinion on these financial statements based on our audits.
We conducted our audits in accordance with generally accepted auditing
standards. Those standards require that we plan and perform the audit to obtain
reasonable assurance about whether the financial statements are free of material
misstatement. An audit includes examining, on a test basis, evidence supporting
the amounts and disclosures in the financial statements. An audit also includes
assessing the accounting principles used and significant estimates made by
management, as well as evaluating the overall financial statement presentation.
We believe that our audits provide a reasonable basis for our opinion.
In our opinion, the financial statements referred to above present fairly, in
all material respects, the consolidated financial position of Eli Lilly and
Company and subsidiaries at December 31, 1997 and 1996, and the consolidated
results of their operations and their cash flows for each of the three years in
the period ended December 31, 1997, in conformity with generally accepted
accounting principles.
Ernst & Young LLP
Indianapolis, Indiana
January 30, 1998
35
<PAGE>
<PAGE>
Appendix to Exhibit 13
Graphs in Annual Report to Shareholders
for the Year Ended December 31, 1997
Set forth below, converted to tabular format, are the graphs contained in the
paper format of the portions of the Company's Annual Report to Shareholders that
are contained in this Exhibit 13.
Graph #1--Net Sales
($ millions)
Year Amount
- ---- ------
1988 $2,943.7
1989 3,391.0
1990 4,178.3
1991 4,533.4
1992 4,963.1
1993 5,198.5
1994 5,711.6
1995 6,763.8
1996 7,346.6
1997 8,517.6
Net sales increased 16 percent as strong worldwide volume growth of 18 percent
and a slight increase in global selling prices were partially offset by
unfavorable exchange rates.
Graph #2--Net Sales
($ millions; percentages represent changes from 1996)
Percent Change
Class Amount from 1996
- ----- ------ --------------
Prozac $2,559.2 9%
Anti-Infectives 1,272.5 (12)%
Insulins 1,073.3 9%
Zyprexa 730.2 740%
Animal Health 589.8 8%
Axid 526.5 (1)%
Humatrope 259.7 (3)%
ReoPro 254.4 70%
Gemzar 174.8 183%
In 1997, sales of three of the company's newer products, Zyprexa, Gemzar, and
ReoPro, and continued growth in sales of Prozac contributed to the 16 percent
increase in net sales. In total, 14 products, spanning all therapeutic classes,
had annual sales in excess of $100 million.
36
<PAGE>
<PAGE>
Appendix to Exhibit 13 Continued
Graph #3--Sales Outside the U.S.
($ millions)
Year Amount
- ---- ------
1988 $1,143.3
1989 1,335.7
1990 1,636.9
1991 1,807.0
1992 1,996.2
1993 2,097.5
1994 2,430.2
1995 2,950.9
1996 3,081.0
1997 3,105.9
Sales volume growth of 12 percent outside the U.S. was offset by an adverse
exchange rate impact of 9 percent and price declines of 2 percent, resulting in
net sales growth outside the U.S. of 1 percent in 1997.
Graph #4--Research and Development Expenses
($ millions)
Year Amount
- ---- ------
1993 $ 755.0
1994 838.7
1995 1,042.3
1996 1,189.5
1997 1,382.0
Worldwide research and development expenditures increased 16 percent in 1997,
the same rate as sales, in support of the company's strong pipeline, which
includes 16 compounds in Phase II or Phase III clinical trials.
Graph #5--Income (Loss) from Continuing Operations
($ millions)
Year Amount
- ---- ------
1993 $ 464.8
1994 1,185.1
1995 1,306.6
1996 1,523.5
1997 reported (385.1)
1997 normalized 1,774.4
In 1997, the company recognized the first annual net loss in its history due to
the asset impairment charge, which was offset somewhat by the DowElanco gain.
Without these significant events, income from continuing operations would have
increased 16 percent, to $1.77 billion. The year 1993 includes restructuring and
special charges. See notes 2, 3 and 4 to the consolidated financial statements.
37
<PAGE>
<PAGE>
Appendix to Exhibit 13 Continued
Graph #6--Economic Value Added
($ millions)
Year Amount
- ---- ------
1995 $333
1996 460
1997 751
In 1997, Lilly's Economic Valued Added (EVA) was $751 million, an increase of 63
percent, reflecting the company's commitment to delivering exceptional
shareholder value.
Graph #7--Capital Expenditures
($ millions)
Year Amount
- ---- ------
1993 $633.5
1994 576.5
1995 551.3
1996 443.9
1997 366.3
Capital expenditures declined 17 percent from the 1996 level to their lowest
level in nine years.
Graph #8--Dividends Paid per Share
(dollars)
Year Amount
- ---- ------
1993 $.605
1994 .625
1995 .655
1996 .685
1997 .74
Dividends paid during 1997 were increased twice totaling 8 percent. Nineteen
ninety-seven was the 30th consecutive year in which dividends were increased.
These increases reflect the company's continued commitment to its shareholders.
38
<PAGE>
<PAGE>
Exhibit 21-List of Subsidiaries and Affliates
The following are the subsidiaries and affiliated corporations
of the Company at December 31, 1997.
Certain subsidiaries have been omitted since they are not
significant in the aggregate.
<TABLE>
<CAPTION>
State or Jurisdiction
of Incorporation
or Organization
---------------------------
<S> <C>
ELI LILLY AND COMPANY Indiana
Eli Lilly International Corporation Indiana
Eli Lilly Iran, S.A. Iran
ELCO Insurance Company, Ltd. Bermuda
Eli Lilly Interamerica, Inc. Indiana
Eli Lilly do Brasil Limitada Brazil
Elanco Quimica Limitada Brazil
Darilor Sociedad Anonima Uruguay
Beimirco Sociedad Anonima Uruguay
Eli Lilly Interamerica Inc., y Compania Limitada Chile
STC Pharmaceuticals, Inc. Indiana
Dista, Inc. Indiana
Eli Lilly de Centro America, S.A. Guatemala
Eli Lilly de Centro America, Sociedad Anonima Costa Rica
Eli Lilly y Compania de Mexico, S.A. de C.V. Mexico
Dista Mexicana, S.A. de C.V. Mexico
Eli Lilly Industries, Inc. Delaware
Lilly del Caribe, Inc. Cayman Isls.
Eli Lilly and Company (Taiwan), Inc. Taiwan
Control Diabetes Services, Inc. Indiana
PCS Holding Corporation Delaware
Clinical Pharmaceuticals, Inc. Delaware
Convenience Office Prescriptions California
PCS Health Systems, Inc. Delaware
PCS of New York, Inc. New York
PCS Services, Inc. Delaware
PCS Mail Services, Inc. Delaware
Integrated Medical Systems, Inc. Colorado
IMS-NET of Arizona, Inc. Arizona
IMS-NET of Illinois, Inc. Illinois
Illinois Medical Information Network, Inc. Illinois
IMS-NET of Northern California, Inc. California
IMS-NET of Sacramento, Inc. California
IMS-NET of Alabama, Inc. Alabama
IMS-NET of Central Florida, Inc. Colorado
IMS-NET of Colorado, Inc. Colorado
IMS-NET of Kansas City, Inc. Colorado
Indiana Medical Communication Network L.L.C. Colorado
Medical Communication Networks, Inc. California
Minnesota Medical Communication Network L.L.C. Colorado
</TABLE>
Page 1
<PAGE>
<PAGE>
Exhibit 21-List of Subsidiaries and Affliates
The following are the subsidiaries and affiliated corporations
of the Company at December 31, 1997.
<TABLE>
<CAPTION>
State or Jurisdiction
of Incorporation
or Organization
---------------------------
<S> <C>
ELI LILLY AND COMPANY (Cont'd)
ELCO Dominicana, S.A. Dominican Rep.
ELCO International Sales Corporation Virgin Is.-US
Eli Lilly Group Limited England
Eli Lilly & Co. LTD. England
Dista Products Limited England
Eli Lilly & CO (Ireland) Trustee Limited Ireland
Lilly Industries England
Lilly Research Centre Limited England
Elanco Products Limited England
Creative Packaging Limited England
Greenfield Pharmaceuticals Limited England
Lilly Medical Instruments Limited England
Eli Lilly (Basingstoke) Limited England
Eli Lilly UK Limited England
Eli Lilly Group Pension Trustees Limited England
Lilly Deutschland GmbH Germany
Eli Lilly (Suisse) S.A. & Co. Beteiligungs-KG Germany
Beiersdorf-Lilly GmbH Germany
LIGEMA Lilly Gesundheitsmanagement GmbH Germany
Eli Lilly & Co. (Ireland) Limited Ireland
Eli Lilly Asia, Inc. Delaware
Eli Lilly Australia Pty. Limited Australia
Eli Lilly Australia Custodian Pty. Limited Bermuda
AZA Research Pty. Ltd. Australia
Eli Lilly and Company (N.Z.) Limited New Zealand
Eli Lilly (NZ) Staff Benefits Custodian Limited New Zealand
Integrated Disease Management (NZ) Limited New Zealand
E L Management Incorporated Delaware/Nova Scotia
Eli Lilly Canada Inc. Canada
Eli Lilly S.A. Switzerland
</TABLE>
Page 2
<PAGE>
<PAGE>
Exhibit 21-List of Subsidiaries and Affliates
The following are the subsidiaries and affiliated corporations
of the Company at December 31, 1997.
<TABLE>
<CAPTION>
State or Jurisdiction
of Incorporation
or Organization
---------------------------
<S> <C>
ELI LILLY S.A. (Cont'd) Switzerland
Eli Lilly Export S.A. Switzerland
LDPR International, Inc. Puerto Rico
GEMS Services, S.A. Belgium
T. P. Eli Lilly and Elanco D.O.O. Yugoslavia
Elanco Trustees Limited Ireland
Kinsale Financial Services, Ltd. Ireland
Eli Lilly (Suisse) S.A. Switzerland
Eli Lilly Vostok SA, Geneva Switzerland
Eli Lilly MHC S.A.R.L. Switzerland
Eli Lilly Mauritius Mauritius
Oldfields Financial Management S.A. Switzerland
Eli Lilly Suzhou Pharmaceutical Company Limited China
Eli Lilly Nederland B.V. Netherlands
Eli Lilly Ges.m.b.H. Austria
Lilly Development Centre S.A. Belgium
Lilly Services S.A. Belgium
Lilly Clinical Operations S.A. Belgium
Eli Lilly Benelux, S.A. Belgium
Eli Lilly CR s.r.o. Czech Repub.
Eli Lilly Danmark A/S Denmark
Eli Lilly Egypt Egypt
OY Eli Lilly Finland Ab Finland
Lilly France S.A. France
Elsa France, S.A. France
Pharmaserve - Lilly S.A.C.I. Greece
Pharmabrand, S.A.C.I. Greece
PRAXICO Ltd. Hungary
Lilly Hungaria KFT Hungary
Eli Lilly (Philippines), Incorporate Philippines
Eli Lilly Ranbaxy Limited India
Eli Lilly Israel Ltd. Israel
Dista Italia S.r.l. Italy
Eli Lilly Italia S.p.A. Italy
</TABLE>
Page 3
<PAGE>
<PAGE>
Exhibit 21-List of Subsidiaries and Affliates
The following are the subsidiaries and affiliated corporations
of the Company at December 31, 1997.
<TABLE>
<CAPTION>
State or Jurisdiction
of Incorporation
or Organization
---------------------------
<S> <C>
ELI LILLY S.A. (Cont'd)
Eli Lilly Nederland B.V. (Cont'd) Netherlands
Eli Lilly Japan K.K. Japan
Daewoong Lilly Pharmaceutical Co., Ltd. Korea
Elanco Animal Health, Korea, Ltd. Korea
Eli Lilly Malaysia Sdn Bhd. Malaysia
Damsen Trading Limited Malta
Eli Lilly Maroc S.a.r.l. Morocco
ELCO Production Services B.V. Netherlands
Eli Lilly Norge A.S. Norway
Eli Lilly Pakistan (Pvt.) Ltd. Pakistan
Eli Lilly Polska Sp. z.o.o. (Ltd.) Poland
Lilly Grodzisk Sp. z.o.o. Poland
Vitalia Pharma Sp. Z.o.o. Poland
Dista-Produtos Quimicos & Farmaceuticos, LDA Portugal
Lilly-Farma, Produtos Farmaceuticos, Lda. Portugal
Eli Lilly Asia Pacific Pte. Ltd. Singapore
Lilly-NUS Centre for Clinical Pharmacology Pte. Ltd. Singapore
Eli Lilly (S.A.) (Proprietary) Limited South Africa
Elanco-Valquimica, S.A. Spain
Dista, S.A. Spain
Lilly, S.A. Spain
Geserco, S.A. Spain
Eli Lilly Sweden AB Sweden
Lilly Ilac Ticaret A.S. Turkey
Eli Lilly y Compania de Venezuela, S.A. Venezuela
Dista Products & Compania Venezuela S.A. Venezuela
</TABLE>
Page 4
<PAGE>
<PAGE>
EXHIBIT 23. CONSENT OF INDEPENDENT AUDITORS
We consent to the incorporation by reference in this Annual Report (Form 10-K)
of Eli Lilly and Company of our report dated January 30, 1998, included in the
1997 Annual Report to Shareholders of Eli Lilly and Company.
We also consent to the incorporation by reference in Registration Statement
Number 33-29482 on Form S-8 dated June 23, 1989, in Registration Statement
Number 33-37341 on Form S-8 dated October 17, 1990, in Registration Statement
Number 33-58466 on Form S-3 dated February 17, 1993, in Registration Statement
Number 33-50783 on Form S-8 dated October 27, 1993, in Registration Statement
Number 33-56141 on Form S-8 dated October 24, 1994 and in Registration Statement
Number 333-02021 on Form S-8 dated March 28, 1996 of our report dated January
30, 1998 with respect to the consolidated financial statements incorporated
herein by reference, and our report included in the preceding paragraph with
respect to the consolidated financial statements incorporated by reference in
the Annual Report (Form 10-K) of Eli Lilly and Company.
Ernst & Young LLP
Indianapolis, Indiana
March 20, 1998
<PAGE>
<TABLE> <S> <C>
<ARTICLE> 5
<MULTIPLIER> 1,000
<S> <C>
<PERIOD-TYPE> YEAR
<FISCAL-YEAR-END> DEC-31-1997
<PERIOD-END> DEC-31-1997
<CASH> 1,947,541
<SECURITIES> 77,101
<RECEIVABLES> 1,597,675
<ALLOWANCES> 53,330
<INVENTORY> 900,730
<CURRENT-ASSETS> 5,320,736
<PP&E> 7,034,880
<DEPRECIATION> 2,933,155
<TOTAL-ASSETS> 12,577,436
<CURRENT-LIABILITIES> 4,191,617
<BONDS> 2,326,110
0
0
<COMMON> 694,701
<OTHER-SE> 3,950,911
<TOTAL-LIABILITY-AND-EQUITY> 12,577,436
<SALES> 8,086,065
<TOTAL-REVENUES> 8,517,628
<CGS> 2,050,070
<TOTAL-COSTS> 2,362,929
<OTHER-EXPENSES> 6,139,442<F2>
<LOSS-PROVISION> 0<F1>
<INTEREST-EXPENSE> 234,097
<INCOME-PRETAX> 510,200
<INCOME-TAX> 895,330
<INCOME-CONTINUING> (385,130)
<DISCONTINUED> 0
<EXTRAORDINARY> 0
<CHANGES> 0
<NET-INCOME> (385,130)
<EPS-PRIMARY> (.35)<F3>
<EPS-DILUTED> (.35)<F3>
<FN>
<F1>-The information called for is not given as the balances are not
individually significant.
<F2>-Amounts include research and development, selling and general and
administrative expenses and a $2,443 million noncash charge due to an
asset impairment.
<F3>-Per-share amounts reflect the 2-for-1 stock split paid on October 15,
1997, to shareholders of record on September 24, 1997. Prior Financial
Data Schedules have not been restated for the stock split.
</FN>
<PAGE>
<TABLE> <S> <C>
<ARTICLE> 5
<RESTATED>
<MULTIPLIER> 1,000
<S> <C>
<PERIOD-TYPE> YEAR
<FISCAL-YEAR-END> DEC-31-1995
<PERIOD-END> DEC-31-1995
<CASH> 999,549
<SECURITIES> 84,644
<RECEIVABLES> 1,575,605
<ALLOWANCES> 55,076
<INVENTORY> 839,564
<CURRENT-ASSETS> 4,138,561
<PP&E> 6,828,340
<DEPRECIATION> 2,589,026
<TOTAL-ASSETS> 14,412,503
<CURRENT-LIABILITIES> 4,966,985
<BONDS> 2,592,894
0
0
<COMMON> 355,564
<OTHER-SE> 5,077,059
<TOTAL-LIABILITY-AND-EQUITY> 14,412,503
<SALES> 6,504,386
<TOTAL-REVENUES> 6,763,804
<CGS> 1,721,110
<TOTAL-COSTS> 1,885,701
<OTHER-EXPENSES> 2,896,297<F5>
<LOSS-PROVISION> 0<F4>
<INTEREST-EXPENSE> 286,317
<INCOME-PRETAX> 1,765,641
<INCOME-TAX> 459,067
<INCOME-CONTINUING> 1,306,575
<DISCONTINUED> 984,349
<EXTRAORDINARY> 0
<CHANGES> 0
<NET-INCOME> 2,290,924
<EPS-PRIMARY> 2.01
<EPS-DILUTED> 1.99
<FN>
<F4>-The information called for is not given as the balances are not
individually significant.
<F5>-Amounts include research and development, selling and general and
administrative expenses.
</FN>
<PAGE>
<TABLE> <S> <C>
<ARTICLE> 5
<RESTATED>
<MULTIPLIER> 1,000
<S> <C>
<PERIOD-TYPE> 3-MOS
<FISCAL-YEAR-END> DEC-31-1996
<PERIOD-END> MAR-31-1996
<CASH> 898,400
<SECURITIES> 95,004
<RECEIVABLES> 1,552,083
<ALLOWANCES> 57,415
<INVENTORY> 843,670
<CURRENT-ASSETS> 3,847,465
<PP&E> 6,837,463
<DEPRECIATION> 2,623,341
<TOTAL-ASSETS> 14,160,373
<CURRENT-LIABILITIES> 4,436,476
<BONDS> 2,576,183
0
0
<COMMON> 355,564
<OTHER-SE> 5,490,036
<TOTAL-LIABILITY-AND-EQUITY> 14,160,373
<SALES> 1,705,525
<TOTAL-REVENUES> 1,783,268
<CGS> 460,376
<TOTAL-COSTS> 517,932
<OTHER-EXPENSES> 736,046<F7>
<LOSS-PROVISION> 0<F6>
<INTEREST-EXPENSE> 69,880
<INCOME-PRETAX> 523,793
<INCOME-TAX> 134,611
<INCOME-CONTINUING> 389,182
<DISCONTINUED> 0
<EXTRAORDINARY> 0
<CHANGES> 0
<NET-INCOME> 389,182
<EPS-PRIMARY> .36
<EPS-DILUTED> .35
<FN>
<F6>-The information called for is not given as the balances are not
individually significant.
<F7>-Amounts include research and development, selling and general and
administrative expenses.
</FN>
<PAGE>
<TABLE> <S> <C>
<ARTICLE> 5
<RESTATED>
<MULTIPLIER> 1,000
<S> <C>
<PERIOD-TYPE> 6-MOS
<FISCAL-YEAR-END> DEC-31-1996
<PERIOD-END> JUN-30-1996
<CASH> 1,125,041
<SECURITIES> 95,054
<RECEIVABLES> 1,500,597
<ALLOWANCES> 64,680
<INVENTORY> 870,364
<CURRENT-ASSETS> 4,058,896
<PP&E> 6,886,430
<DEPRECIATION> 2,645,695
<TOTAL-ASSETS> 14,258,814
<CURRENT-LIABILITIES> 4,517,243
<BONDS> 2,586,880
0
0
<COMMON> 355,564
<OTHER-SE> 5,538,121
<TOTAL-LIABILITY-AND-EQUITY> 14,258,814
<SALES> 3,308,353
<TOTAL-REVENUES> 3,481,579
<CGS> 896,385
<TOTAL-COSTS> 1,023,136
<OTHER-EXPENSES> 1,488,393<F8>
<LOSS-PROVISION> 0<F9>
<INTEREST-EXPENSE> 145,414
<INCOME-PRETAX> 989,113
<INCOME-TAX> 254,201
<INCOME-CONTINUING> 734,912
<DISCONTINUED> 0
<EXTRAORDINARY> 0
<CHANGES> 0
<NET-INCOME> 734,912
<EPS-PRIMARY> .67
<EPS-DILUTED> .66
<FN>
<F8>-Amounts include research and development, selling and
general and administrative expenses.
<F9>-The information called for is not given as the balances
are not individually significant.
</FN>
<PAGE>
<TABLE> <S> <C>
<ARTICLE> 5
<RESTATED>
<MULTIPLIER> 1,000
<S> <C>
<PERIOD-TYPE> 9-MOS
<FISCAL-YEAR-END> DEC-31-1996
<PERIOD-END> SEP-30-1996
<CASH> 738,108
<SECURITIES> 128,324
<RECEIVABLES> 1,693,370
<ALLOWANCES> 77,017
<INVENTORY> 878,275
<CURRENT-ASSETS> 3,860,819
<PP&E> 7,007,920
<DEPRECIATION> 2,722,141
<TOTAL-ASSETS> 14,052,805
<CURRENT-LIABILITIES> 4,194,128
<BONDS> 2,582,340
0
0
<COMMON> 355,564
<OTHER-SE> 5,671,087
<TOTAL-LIABILITY-AND-EQUITY> 14,052,805
<SALES> 5,016,934
<TOTAL-REVENUES> 5,285,524
<CGS> 1,330,610
<TOTAL-COSTS> 1,525,996
<OTHER-EXPENSES> 2,252,216<F10>
<LOSS-PROVISION> 0<F11>
<INTEREST-EXPENSE> 219,499
<INCOME-PRETAX> 1,548,518
<INCOME-TAX> 397,969
<INCOME-CONTINUING> 1,150,549
<DISCONTINUED> 0
<EXTRAORDINARY> 0
<CHANGES> 0
<NET-INCOME> 1,150,549
<EPS-PRIMARY> 1.05
<EPS-DILUTED> 1.03
<FN>
<F10>-Amounts include research and development, selling
and general and administrative expenses.
<F11>-The information called for is not given as the
balances are not individually significant.
</FN>
<PAGE>
<TABLE> <S> <C>
<ARTICLE> 5
<RESTATED>
<MULTIPLIER> 1,000
<S> <C>
<PERIOD-TYPE> YEAR
<FISCAL-YEAR-END> DEC-31-1996
<PERIOD-END> DEC-31-1996
<CASH> 813,678
<SECURITIES> 141,407
<RECEIVABLES> 1,556,990
<ALLOWANCES> 82,351
<INVENTORY> 881,397
<CURRENT-ASSETS> 3,891,285
<PP&E> 7,096,400
<DEPRECIATION> 2,789,429
<TOTAL-ASSETS> 14,307,170
<CURRENT-LIABILITIES> 4,222,193
<BONDS> 2,516,484
0
0
<COMMON> 355,564
<OTHER-SE> 5,744,576
<TOTAL-LIABILITY-AND-EQUITY> 14,307,170
<SALES> 6,974,347
<TOTAL-REVENUES> 7,346,594
<CGS> 1,848,282
<TOTAL-COSTS> 2,118,413
<OTHER-EXPENSES> 3,181,397<F13>
<LOSS-PROVISION> 0<F12>
<INTEREST-EXPENSE> 288,835
<INCOME-PRETAX> 2,031,290
<INCOME-TAX> 507,821
<INCOME-CONTINUING> 1,523,470
<DISCONTINUED> 0
<EXTRAORDINARY> 0
<CHANGES> 0
<NET-INCOME> 1,523,470
<EPS-PRIMARY> 1.39
<EPS-DILUTED> 1.36
<FN>
<F12>-The information called for is not given as the balances are not
individually significant.
<F13>-Amounts include research and development, selling and general and
administrative expenses.
</FN>
<PAGE>
<TABLE> <S> <C>
<ARTICLE> 5
<RESTATED>
<MULTIPLIER> 1,000
<S> <C>
<PERIOD-TYPE> 3-MOS
<FISCAL-YEAR-END> DEC-31-1997
<PERIOD-END> MAR-31-1997
<CASH> 1,042,119
<SECURITIES> 75,361
<RECEIVABLES> 1,620,415
<ALLOWANCES> 66,336
<INVENTORY> 876,264
<CURRENT-ASSETS> 4,275,747
<PP&E> 7,002,555
<DEPRECIATION> 2,808,226
<TOTAL-ASSETS> 14,513,618
<CURRENT-LIABILITIES> 4,061,749
<BONDS> 2,509,649
0
0
<COMMON> 355,564
<OTHER-SE> 6,213,909
<TOTAL-LIABILITY-AND-EQUITY> 14,513,618
<SALES> 1,833,779
<TOTAL-REVENUES> 1,953,000
<CGS> 449,151
<TOTAL-COSTS> 541,345
<OTHER-EXPENSES> 772,856<F14>
<LOSS-PROVISION> 0<F15>
<INTEREST-EXPENSE> 60,631
<INCOME-PRETAX> 576,829
<INCOME-TAX> 144,213
<INCOME-CONTINUING> 432,616
<DISCONTINUED> 0
<EXTRAORDINARY> 0
<CHANGES> 0
<NET-INCOME> 432,616
<EPS-PRIMARY> .39
<EPS-DILUTED> .38
<FN>
<F14>-Amounts include research and development, marketing and
administrative expenses.
<F15>-The information called for is not given as the balances
are not individually significant.
</FN>
<PAGE>
<TABLE> <S> <C>
<ARTICLE> 5
<RESTATED>
<MULTIPLIER> 1,000
<S> <C>
<PERIOD-TYPE> 6-MOS
<FISCAL-YEAR-END> DEC-31-1997
<PERIOD-END> JUN-30-1997
<CASH> 1,853,011
<SECURITIES> 100,138
<RECEIVABLES> 1,449,845
<ALLOWANCES> 62,019
<INVENTORY> 945,831
<CURRENT-ASSETS> 4,992,080
<PP&E> 7,039,912
<DEPRECIATION> 2,883,445
<TOTAL-ASSETS> 12,288,903
<CURRENT-LIABILITIES> 3,699,847
<BONDS> 2,501,817
0
0
<COMMON> 355,564
<OTHER-SE> 4,314,379
<TOTAL-LIABILITY-AND-EQUITY> 12,288,903
<SALES> 3,724,943
<TOTAL-REVENUES> 3,941,728
<CGS> 929,557
<TOTAL-COSTS> 1,090,131
<OTHER-EXPENSES> 4,115,329<F16>
<LOSS-PROVISION> 0<F17>
<INTEREST-EXPENSE> 123,090
<INCOME-PRETAX> (712,096)
<INCOME-TAX> 587,384
<INCOME-CONTINUING> (1,299,480)
<DISCONTINUED> 0
<EXTRAORDINARY> 0
<CHANGES> 0
<NET-INCOME> (1,299,480)
<EPS-PRIMARY> (1.18)
<EPS-DILUTED> (1.19)
<FN>
<F16>-Amounts include research and development, selling and
general administrative expenses, and asset impairment.
<F17>-The information called for is not given as the balances
are not individually significant.
</FN>
<PAGE>
<TABLE> <S> <C>
<ARTICLE> 5
<RESTATED>
<MULTIPLIER> 1,000
<S> <C>
<PERIOD-TYPE> 9-MOS
<FISCAL-YEAR-END> DEC-31-1997
<PERIOD-END> SEP-30-1997
<CASH> 1,504,144
<SECURITIES> 36,775
<RECEIVABLES> 1,641,117
<ALLOWANCES> 61,444
<INVENTORY> 914,719
<CURRENT-ASSETS> 4,609,102
<PP&E> 7,023,242
<DEPRECIATION> 2,928,055
<TOTAL-ASSETS> 11,819,157
<CURRENT-LIABILITIES> 3,647,031
<BONDS> 2,343,798
0
0
<COMMON> 702,020
<OTHER-SE> 3,688,873
<TOTAL-LIABILITY-AND-EQUITY> 11,819,157
<SALES> 5,783,936
<TOTAL-REVENUES> 6,101,770
<CGS> 1,442,998
<TOTAL-COSTS> 1,677,886
<OTHER-EXPENSES> 5,047,876<F18>
<LOSS-PROVISION> 0<F19>
<INTEREST-EXPENSE> 180,432
<INCOME-PRETAX> (99,841)
<INCOME-TAX> 742,722
<INCOME-CONTINUING> (842,563)
<DISCONTINUED> 0
<EXTRAORDINARY> 0
<CHANGES> 0
<NET-INCOME> (842,563)
<EPS-PRIMARY> (.77)
<EPS-DILUTED> (.79)
<FN>
<F18>-Amounts include research and development, selling and
general and administrative expenses, and asset impairment.
<F19>-The information called for is not given as the balances are
not individually significant.
</FN>
<PAGE>
<PAGE>
EXHIBIT 99 CAUTIONARY STATEMENT UNDER PRIVATE SECURITIES
LITIGATION REFORM ACT OF 1995 - "SAFE HARBOR" FOR
FORWARD LOOKING DISCLOSURES
Certain forward-looking statements are included in this Form 10-K and may be
made by Company spokespersons based on current expectations of management. All
forward-looking statements made by the Company are subject to risks and
uncertainties. Certain factors, including but not limited to those listed below,
may cause actual results to differ materially from current expectations and
historical results.
- - Economic factors over which the Company has no control, including changes
in inflation, interest rates and foreign currency exchange rates.
- - Competitive factors including generic competition as patents on key
products, such as Prozac, expire; pricing pressures, both in the U.S. and
abroad, primarily from managed care groups and government agencies; and
technological advances and patents obtained by competitors.
- - Governmental factors including laws and regulations and judicial decisions
at the state and federal level related to Medicare, Medicaid and healthcare
reform; and laws and regulations affecting international operations.
- - The difficulties and uncertainties inherent in new product development. New
product candidates that appear promising in development may fail to reach
the market because of efficacy or safety concerns, inability to obtain
necessary regulatory approvals, difficulty or excessive costs to
manufacture, or infringement of the patents or intellectual property rights
of others.
- - Delays and uncertainties in the FDA approval process and the approval
processes in other countries, resulting in lost market opportunity.
- - Unexpected safety or efficacy concerns arising with respect to marketed
products, whether or not scientifically justified, leading to product
recalls, withdrawals or declining sales.
- - Legal factors including unanticipated litigation of product liability
claims; antitrust litigation; environmental matters; and patent disputes
with competitors which could preclude commercialization of products or
negatively affect the profitability of existing products.
- - Future difficulties obtaining or the inability to obtain existing levels of
product liability insurance.
- - Changes in tax laws, including the amendment to the Section 936 income tax
credit, and future changes in tax laws related to the remittance of foreign
earnings or investments in foreign countries with favorable tax rates.
- - Changes in accounting standards promulgated by the Financial Accounting
Standards Board, the Securities and Exchange Commission, and the American
Institute of Certified Public Accountants which are adverse to the Company.
- - Internal factors such as changes in business strategies and the impact of
restructurings and business combinations.
- - The Company's statement that it expects to complete the Year 2000
modifications before December 31, 1999, is based on management's best
estimate, which was derived utilizing numerous assumptions of future
events, including the continued availability of certain resources, third
party modification plans and other factors. However, there can be no
guarantee that timely completion will be achieved and actual results could
differ
<PAGE>
<PAGE>
EXHIBIT 99 (Continued)
materially from those anticipated. Specific factors that might cause
such material differences include, but are not limited to, the availability
and cost of personnel trained in this area, the ability to locate and
correct all relevant computer codes, and similar uncertainties.
<PAGE>
